Methods of treating TGF beta-related disorders with Anti-transforming growth factor beta 3 antibodies
The use of a specifically designed anti-TGFβ3 antibody to inhibit TGFβ3 activity addresses the safety and efficacy challenges of current therapies for fibrotic conditions, offering a more effective treatment for systemic sclerosis and pulmonary fibrosis with reduced toxicity.
Patent Information
- Application Number
- PCT/US2023/070760
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2023-07-21
- Publication Date
- 2024-12-05
AI Technical Summary
Current therapies for fibrotic conditions, such as systemic sclerosis and idiopathic pulmonary fibrosis, face challenges due to safety issues and inefficacy of pan-TGFp inhibitors, which often result in undesirable toxicity and adverse events.
Administration of a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFβ3) antibody, specifically designed with defined CDR sequences for the heavy and light chain variable regions, to inhibit TGFβ3 activity and its binding to TGFBR2, thereby treating TGFβ-related disorders like systemic sclerosis, idiopathic pulmonary fibrosis, and progressive fibrotic interstitial lung disease.
The anti-TGFβ3 antibody effectively treats TGFβ-related disorders by inhibiting TGFβ3 activity, reducing fibrosis and associated complications, while minimizing adverse effects, providing a safer and more efficacious therapeutic option compared to existing treatments.
Smart Images

Figure IMGF000031_0001 
Figure IMGF000041_0001 
Figure IMGF000042_0001
Abstract
Description
METHODS OF TREATING TGF BETA-RELATED DISORDERS WITH ANTITRANSFORMING GROWTH FACTOR BETA 3 ANTIBODIESCROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority and benefit from United States Provisional Application No. 63 / 470,076, filed May 31, 2023, the contents of which are hereby incorporated by reference in their entireties.TECHNICAL FIELD
[0002] The present disclosure pertains to the field of treating fibrotic conditions, including systemic sclerosis, with anti -transforming growth factor beta 3 (TGF[33) monoclonal antibodies.SEQUENCE LISTING
[0003] The instant disclosure contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on July 21, 2023, is named 000218-0073-W01_SL.xml and is 10,659 bytes in size.BACKGROUND
[0004] TGFP-related disorders include fibrosis, which is a fibrotic condition of the lung, liver, heart, kidney, pancreas, eye, and / or skin.
[0005] TGFP comprises a pleiotropic set of three cytokines - TGFpi, TGFP2, and TGFP3 - that play a role in cell differentiation, tissue development, wound repair, immunoregulation, and, when dysregulated, tissue fibrosis. In the case of interstitial lung diseases (ILD) such as idiopathic pulmonary fibrosis (IPF), TGFP activity is implicated in multiple aspects of disease pathogenesis. Genetic risk for IPF is conferred by mutations in genes expressed in lung epithelial cells that increase their susceptibility to injury and / or compromise their regenerative capacity. This epithelial stress or damage can activate innate immune cells such as alveolar macrophages to produce cytokines that activate mesenchymal cells to initiate a wound-healing response by proliferating, migrating, differentiating into myofibroblasts, and secreting extracellular matrix (ECM). TGFP can contribute to many of these processes andhas been shown to promote apoptosis of lung epithelial cells while promoting activation, differentiation, and survival of myofibroblasts.
[0006] Systemic sclerosis (SSc) is a rare connective tissue disease involving fibrosis and microvascular damage to the skin, underlying tissues, blood vessels, and major organs. The pathogenesis of SSc is not yet fully understood. Both genetic and environmental factors may lead to microvascular dysfunction and autoimmune events at disease onset that give way to progressive disease. SSc is most prevalent in adults (age 30-50 years) and primarily affects women. SSc incidence and prevalence vary by geographic region and ethnicity (greater in European and lesser in Asian ancestry). In the United States, the incidence is estimated to be 14-21 cases per 1,000,000 in 1 year. Multiple population-based studies estimate the prevalence of SSc in the United States at 105-300 cases per 1,000,000.
[0007] SSc is characterized by initial acral skin sclerosis of the hands, feet, and face that can progress to involve the entire body diffusely. There are two major subsets of patients divided according to the extent of skin involvement: limited cutaneous systemic sclerosis (IcSSc) and diffuse cutaneous systemic sclerosis (dcSSc). dcSSc is associated with a greater extent of skin involvement and often rapid progression of internal organ manifestations. The extent and severity of skin sclerosis have been shown to be predictive of internal organ involvement and overall survival. In IcSSc, skin sclerosis is restricted to distal extremities; however, these patients also develop internal organ complications, most often interstitial lung disease (ILD) and pulmonary arterial hypertension.
[0008] Other features of SSc include Raynaud phenomenon and the involvement of the gastrointestinal (GI) tract, heart, lungs, kidneys, and musculoskeletal system. A large proportion of SSc patients also have associated ILD, with SSc-ILD present in up to 75% of patients. Renal, cardiac, and pulmonary involvement and complications are known predictors of mortality. Infections are a well-known disease complication in SSc.
[0009] TGFp activity is implicated in multiple aspects of SSc disease pathogenesis (Morikawa et al. 2016; Distler et al. 2019). TGFP is also involved in the dysregulation of vascular, connective tissue, and immune components in SSc (Lafyatis 2014). Transforming growth factor beta (TGFP) comprises a pleiotropic set of three cytokines-TGFpi, TGFP2, and TGFp3-that play critical and distinct roles in cell differentiation, tissue development, wound repair, immunoregulation, and, when dysregulated, tissue fibrosis. TGFpi, TGFP2, and TGFP3 are encoded by separate genes that are highly conserved across vertebrates. Genetic deletion of TGFp isoforms and receptors has revealed distinct roles for the threeisoforms in development and homeostasis.
[0010] However, the multifarious homeostatic functions of TGF[3 and complexity in context-dependent mechanisms of TGF[3 activation have contributed to limitations in terms of both safety and efficacy to establish a favorable therapeutic index in interventional studies of TGFP inhibitors in human fibrotic disorders. For example, pan-TGFp inhibitors have been associated with undesirable toxicity and safety issues. In particular, the small molecule ALK5 inhibitors AZ12601011 and AZ12799734 (Anderton et al. (2011) Toxicologic Pathology, 39: 916-924) caused microscopic heart valve lesions in rats, and the pan-TGFp 1D11 antibody (Lonning et al. (2011) Current Pharmaceutical Biotechnology, 12, 2176-2189) caused mice treated with ID 11 to develop histologic lesions, weight loss, nonneoplastic cystic epithelial hyperplasia and inflammation of the tongue and dental dysplasia and epithelial hyperplasia of the gingiva and esophagus. Further, CAT-192 (metelimumab), an antibody predominantly selective for TGFpi, had a high serious adverse event rate with multiple gastric hemorrhages observed in a phase 1-2 study in SSc (Denton A&.R 56:323 (2007)).
[0011] Thus, there remains a need in the art for safe and efficacious therapies for treating fibrotic conditions, including SSc. The present disclosure provides such therapies.SUMMARY OF THE DISCLOSURE
[0012] The present disclosure provides methods for treating a TGFP-related disorder in a subject in need thereof. One aspect of the disclosure provides a method of treating a TGFP- related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGF[33) antibody, wherein the anti-TGF[33 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR- H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0013] The present disclosure provides methods for treating systemic sclerosis, idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof or a method of inhibiting binding of TGF[33 to TGFBR2 in a subject. One aspect of the disclosure provides a method of treating systemic sclerosis in a subject in needthereof, the method comprising administering to the subject a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti- TGFP3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0014] Another aspect of the disclosure provides a method of treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0015] Another aspect of the disclosure provides a method of treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGF[33) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0016] Another aspect of the disclosure provides a method of inhibiting binding of TGFP3 to TGFBR2 in a subject comprising administering to the subject a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti- TGFP3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ IDNO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0017] Another aspect of the disclosure provides a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGF|33) antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0018] Another aspect of the disclosure provides a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0019] Another aspect of the disclosure provides a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0020] Another aspect of the disclosure provides a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti- TGFP3 antibody comprises a) a heavy chain variable region comprising a CDR-H1comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0021] Another aspect of the disclosure provides a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGF|33) antibody for use in inhibiting binding of TGF|33 to TGFBR2 in a subject, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0022] Another aspect of the disclosure provides use of a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody for the manufacture of a medicament for treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0023] Another aspect of the disclosure provides use of a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody for the manufacture of a medicament for treating systemic sclerosis in a subject in need thereof, wherein the anti- TGFP3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0024] Another aspect of the disclosure provides use of a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody for the manufacture of amedicament for treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0025] Another aspect of the disclosure provides use of a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGF|33) antibody for the manufacture of a medicament for treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0026] Another aspect of the disclosure provides use of a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody for the manufacture of a medicament for inhibiting binding of TGFP3 to TGFBR2 in a subject, wherein the anti- TGFP3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0027] In some embodiments, the anti-TGFp3 antibody is administered at a dose of about 50 mg to about 1200 mg. In some embodiments, the anti-TGFp3 antibody is administered at a dose of about 400 mg to about 800 mg. In some embodiments, the anti-TGFp3 antibody is administered at a dose of about 70 mg to about 80 mg. In some embodiments, the anti- TGFP3 antibody is administered at a dose of about 75 mg. In some embodiments, the anti- TGFP3 antibody is administered at a dose of 75 mg. In some embodiments, the anti-TGFp3 antibody is administered at a dose of about 215 mg to about 235 mg. In some embodiments, the anti-TGFp3 antibody is administered at a dose of about 225 mg. In some embodiments,the anti-TGFp3 antibody is administered at a dose of 225 mg. In some embodiments, the anti-TGFp3 antibody is administered at a dose of about 350 mg to about 370 mg. In some embodiments, the anti-TGFp3 antibody is administered at a dose of about 360 mg. In some embodiments, the anti-TGFp3 antibody is administered at a dose of 360 mg. In some embodiments, the anti-TGFp3 antibody is administered at a dose of about 590 mg to about 610 mg. In some embodiments, the anti-TGFp3 antibody is administered at a dose of about 600 mg. In some embodiments, the anti-TGFp3 antibody is administered at a dose of 600 mg. In some embodiments, the anti-TGFp3 antibody is administered at a dose of about 1100 mg to about 1200 mg. In some embodiments, the anti-TGFp3 antibody is administered at a dose of about 1200 mg. In some embodiments, the anti-TGFp3 antibody is administered at a dose of 1200 mg.
[0028] In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of about 50 mg to about 1200 mg. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of about 400 mg to about 800 mg. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of about 70 mg to about 80 mg. In some embodiments, the anti- TGFP3 antibody in the medicament is formulated for administration or is to be administered at a dose of about 75 mg. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of 75 mg. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of about 215 mg to about 235 mg. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of about 225 mg. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of 225 mg. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of about 350 mg to about 370 mg. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of about 360 mg. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of 360 mg. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of about 590 mg to about 610 mg. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of about 600 mg. In some embodiments, theanti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of 600 mg. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of about 1100 mg to about 1200 mg. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of about 1200 mg. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of 1200 mg.
[0029] In some embodiments, the heavy chain variable region (VH) comprises at least 95%, sequence identity to the amino acid sequence of SEQ ID NO: 7. In some embodiments, the heavy chain variable region (VH) comprises the amino acid sequence of SEQ ID NO: 7. In some embodiments, the light chain variable region (VL) comprises at least 95%, sequence identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the light chain variable region (VL) comprises the amino acid sequence of SEQ ID NO: 8. In some embodiments, the heavy chain variable region (VH) comprises at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7 and the light chain variable region (VL) comprises at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the heavy chain variable region (VH) comprises the amino acid sequence of SEQ ID NO: 7 and the light chain variable region (VL) comprises the amino acid sequence of SEQ ID NO: 8.
[0030] In some embodiments, the anti-TGFp3 antibody comprises a heavy (H) chain comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9. In some embodiments, the anti-TGFp3 antibody comprises a heavy (H) chain comprising the amino acid sequence of SEQ ID NO: 9. In some embodiments, the anti-TGFp3 antibody comprises a light (L) chain comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10. In some embodiments, the anti-TGFp3 antibody comprises a light (L) chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the anti-TGFp3 antibody comprises (a) a heavy (H) chain comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9; and (b) a light (L) chain comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10. In some embodiments, the anti-TGFp3 antibody comprises (a) a heavy (H) chain comprising the amino acid sequence of SEQ ID NO: 9; and (b) a light (L) chain comprising the amino acid sequence of SEQ ID NO: 10.
[0031] In some embodiments, the anti-TGFp3 antibody is a monoclonal antibody, a humanized antibody, or a chimeric antibody. In some embodiments, the anti-TGFp3antibody is a humanized antibody. In some embodiments, the anti-TGFp3 antibody is a monoclonal antibody. In some embodiments, the anti-TGFp3 antibody is a full length antibody. In some embodiments, the anti-TGFp3 antibody is an antibody fragment. In some embodiments, the antibody fragment is selected from the group consisting of an Fv, singlechain Fv (scFv), Fab, Fab', or (Fab')2. In some embodiments, the anti-TGFp3 antibody is an IgGl or IgG4 isotype. In some embodiments, the anti-TGFp3 antibody is an IgGl isotype. In some embodiments, the anti-TGFp3 antibody comprises an Fc region. In some embodiments, the anti-TGFp3 antibody comprises a substitution mutation in the Fc region at amino acid residue N297, L234, L235, and / or D265 (EU numbering). In some embodiments, the substitution mutation is selected from the group consisting of N297G, N297A, L234A, L235A, and D265A. In some embodiments, the substitution mutation is N297G.
[0032] In some embodiments, the anti-TGFp3 antibody is administered subcutaneously or intravenously. In some embodiments, the anti-TGFp3 antibody is administered subcutaneously. In some embodiments, the anti-TGFp3 antibody is administered intravenously.
[0033] In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered subcutaneously or intravenously. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered subcutaneously. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered intravenously.
[0034] In some embodiments, the anti-TGFp3 antibody is administered at a frequency selected from the group consisting of Q1W, Q2W, Q3W, Q4W, Q5W, and Q6W. In some embodiments, the anti-TGFp3 antibody is administered at a frequency of Q1W. In some embodiments, the anti-TGFp3 antibody is administered at a frequency of Q2W. In some embodiments, the anti-TGFp3 antibody is administered at a frequency of Q3W. In some embodiments, the anti-TGFp3 antibody is administered at a frequency of Q4W. In some embodiments, the anti-TGFp3 antibody is administered at a frequency of Q5W. In some embodiments, the anti-TGFp3 antibody is administered at a frequency of Q6W. In some embodiments, the anti-TGFp3 antibody is administered monthly (e.g., once a month).
[0035] In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a frequency selected from the group consisting of Q1W, Q2W, Q3W, Q4W, Q5W, and Q6W. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a frequency of Q1W. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated foradministration or is to be administered at a frequency of Q2W. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a frequency of Q3W. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a frequency of Q4W. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a frequency of Q5W. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a frequency of Q6W. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered monthly.
[0036] In some embodiments, the anti-TGFp3 antibody is administered in a dosing regimen comprising more than 1 cycle. In some embodiments, the dosing regimen comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 cycles. In some embodiments, the dosing regimen comprises 1 cycle. In some embodiments, the dosing regimen comprises 2 cycles. In some embodiments, the dosing regimen comprises 3 cycles. In some embodiments, the dosing regimen comprises 4 cycles. In some embodiments, the dosing regimen comprises 5 cycles. In some embodiments, the dosing regimen comprises 10 cycles. In some embodiments, the dosing regimen comprises 11 cycles. In some embodiments, the dosing regimen comprises 12 cycles. In some embodiments, the dosing regimen comprises 13 cycles. In some embodiments, the dosing regimen comprises 14 cycles. In some embodiments, the dosing regimen comprises 15 cycles. In some embodiments, the dosing regimen comprises 16 cycles. In some embodiments, the dosing regimen comprises 17 cycles. In some embodiments, the dosing regimen comprises 18 cycles. In some embodiments, the dosing regimen comprises 19 cycles. In some embodiments, the dosing regimen comprises 20 cycles. In some embodiments, the dosing regimen comprises 21 cycles. In some embodiments, the dosing regimen comprises 22 cycles. In some embodiments, the dosing regimen comprises 23 cycles. In some embodiments, the dosing regimen comprises 24 cycles. In some embodiments, the anti- TGFP3 antibody is administered at a frequency of Q4W in a dosing regimen comprising 3 cycles. In some embodiments, the anti-TGFp3 antibody is administered at a frequency of Q4W in a dosing regimen comprising 13 cycles. In some embodiments, the anti-TGFp3 antibody is administered at a frequency of Q4W in a dosing regimen comprising 16 cycles. In some embodiments, the anti-TGFp3 antibody is administered monthly in a dosing regimen comprising 3 cycles. In some embodiments, the anti-TGFp3 antibody is administeredmonthly in a dosing regimen comprising 13 cycles. In some embodiments, the anti-TGFp3 antibody is administered monthly in a dosing regimen comprising 16 cycles.
[0037] In some embodiments, the anti-TGF|33 antibody in the medicament is formulated for administration or is to be administered in a dosing regimen comprising more than 1 cycle. In some embodiments, the dosing regimen comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 cycles. In some embodiments, the dosing regimen comprises 1 cycle. In some embodiments, the dosing regimen comprises 2 cycles. In some embodiments, the dosing regimen comprises 3 cycles. In some embodiments, the dosing regimen comprises 4 cycles. In some embodiments, the dosing regimen comprises 5 cycles. In some embodiments, the dosing regimen comprises 10 cycles. In some embodiments, the dosing regimen comprises 11 cycles. In some embodiments, the dosing regimen comprises 12 cycles. In some embodiments, the dosing regimen comprises 13 cycles. In some embodiments, the dosing regimen comprises 14 cycles. In some embodiments, the dosing regimen comprises 15 cycles. In some embodiments, the dosing regimen comprises 16 cycles. In some embodiments, the dosing regimen comprises 17 cycles. In some embodiments, the dosing regimen comprises 18 cycles. In some embodiments, the dosing regimen comprises 19 cycles. In some embodiments, the dosing regimen comprises 20 cycles. In some embodiments, the dosing regimen comprises 21 cycles. In some embodiments, the dosing regimen comprises 22 cycles. In some embodiments, the dosing regimen comprises 23 cycles. In some embodiments, the dosing regimen comprises 24 cycles. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a frequency of Q4W in a dosing regimen comprising 3 cycles. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a frequency of Q4W in a dosing regimen comprising 13 cycles. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a frequency of Q4W in a dosing regimen comprising 16 cycles. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered monthly in a dosing regimen comprising 3 cycles. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered monthly in a dosing regimen comprising 13 cycles. In some embodiments, the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered monthly in a dosing regimen comprising 16 cycles.
[0038] In some embodiments, the systemic sclerosis is limited cutaneous systemic sclerosis or diffuse cutaneous systemic sclerosis. In some embodiments, the systemic sclerosis is limited cutaneous systemic sclerosis. In some embodiments, the systemic sclerosis is diffuse cutaneous systemic sclerosis. In some embodiments, the subject is diagnosed with systemic sclerosis as defined by 2013 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) criteria. In some embodiments, the duration of systemic sclerosis in the subject is < 10 years from first non-Raynaud’s symptom. In some embodiments, the subject with diffuse cutaneous systemic sclerosis has a modified Rodnan Skin Score (mRSS) of > 15 mRSS units. In some embodiments, the subject with limited cutaneous systemic sclerosis has a modified Rodnan Skin Score (mRSS) of > 9 mRSS units. In some embodiments, the subject does not have an active rheumatic autoimmune disease other than systemic sclerosis requiring treatment with disease-modifying therapy. In some embodiments, the subject does not have a pulmonary disease with forced vital capacity (FVC) < 50%.
[0039] Another aspect of the disclosure provides methods of diagnosing a subject as having systemic sclerosis, the method comprising detecting in a sample from said subject, the expression level of one or more genes in a TGFP-inducible gene signature set comprising ACTN1, COL4A1, COL15A1, NRP2, PALLD, ADAMTS6, TRIB2, DIO2, COL11A1, HAPLN1, COMP, LRRC15, ASPN, FN1, INHBA, THBS1, ADAMTS12, PRSS23, IGF1, CTHRC1, ITGBL1, COTL1, FZD2, and TAGLN, and wherein the subject is diagnosed with systemic sclerosis if the expression level of the one or more genes is elevated relative to expression levels of corresponding genes in a healthy control set or a reference gene signature.
[0040] In some embodiments, the TGFP-inducible gene signature set consists of ACTN1, COL4A1, COL15A1, NRP2, PALLD, ADAMTS6, TRIB2, DIO2, COL11A1, HAPLN1, COMP, LRRC15, ASPN, FN1, INHBA, THBS1, ADAMTS12, PRSS23, IGF1, CTHRC1, ITGBL1, COTL1, FZD2, and TAGLN. In some embodiments, a gene level is elevated if the expression increases relative to the healthy control set or the reference gene signature is statistically significant, at least two-fold increased, or at least three-fold increased, or at least four-fold increased, relative to the level of the corresponding gene in the healthy control set or reference gene signature. In some embodiments, the expression level of the one or more TGFP-inducible genes is determined by qPCR or microarray analysis. In some embodiments, the subject is a human.
[0041] Another aspect of the disclosure provides an article of manufacture comprising a subcutaneous administration device, wherein the device comprises about 50 mg to about 1200 mg of an anti-TGF[33 antibody, wherein the anti-TGF[33 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0042] Another aspect of the disclosure provides a subcutaneous pharmaceutical composition comprising about 50 mg to about 1200 mg of an anti-TGF[33 antibody, wherein the anti-TGF[33 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and a pharmaceutically acceptable carrier.
[0043] Another aspect of the disclosure provides an intravenous pharmaceutical composition comprising about 50 mg to about 1200 mg of an anti-TGF[33 antibody, wherein the anti-TGF[33 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and a pharmaceutically acceptable carrier.BRIEF DESCRIPTION OF THE DRAWINGS
[0044] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0045] FIG. l is a line graph showing single dose pharmacokinetics of the anti-TGF|33 antibody R07303509 in SCID beige (SCID.bg) mice as average serum concentration time profile measurements following single intravenous administration.
[0046] FIG. 2 shows the study design for the repeat dose toxicokinetics studies in CD-I mice and cynomologus monkeys. TK refers to toxicokinetics.
[0047] FIG. 3 shows a graph of mean serum anti-TGF[33 antibody R07303509 concentrations in CD-I mice following QWxl3 intravenous administration at 10 mg / kg, 50 mg / kg, or 150 mg / kg, or QWxl3 subcutaneous administration at 50 mg / kg to CD-I mice (n=16 males / group). Each symbol within the graph represents mean plasma concentration timepoint ± SD. IV refers to intravenous; QWxl3 refers to every week for 13 weeks; and SC refers to subcutaneous.
[0048] FIG. 4 is a graph showing single dose pharmacokinetics of the anti-TGFp3 antibody R07303509 in cynomolgus monkeys as serum concentration measurements following single intravenous administration.
[0049] FIG. 5 shows a graph of sex-combined mean serum anti-TGF[33 antibody R07303509 concentrations following QWxl3 intravenous administration at 5 mg / kg, 20 mg / kg, or 100 mg / kg, and QWxl3 subcutaneous administration at 50 mg / kg to cynomolgus monkeys. Each symbol within the graph represents mean plasma concentration-timepoint ± SD. IV refers to intravenous; QWxl3 refers to every week for 13 weeks; and SC refers to subcutaneous.
[0050] FIGS. 6A-6F shows graphs of the assessment of target engagement and pharmacodynamics of anti-TGF[33 antibody R07303509 after a single 10 mg / kg dose in cynomolgus monkeys. Longitudinal serum concentrations of total mature TGFP3, COMP and Periostin are shown for individual animals (n=4), either as absolute concentrations (FIG. 6A, FIG. 6C, and FIG. 6E) or as a fold change relative to the pre-dose level at baseline (FIG. 6B, FIG. 6D, and FIG. 6F), respectively. For Cyno #7 and 8, the serum levels of mature TGFP3 remained below the limit of assay detection throughout the study.
[0051] FIGS. 7A and 7B show graphs of pharmacodynamic biomarker data. Mean (+SD) serum periostin (FIG. 7A) and COMP (FIG. 7B) concentrations following QW* 13 intravenous anti-TGFp3 antibody R07303509 administration at 5 mg / kg, 20 mg / kg, and 100 mg / kg, and QW* 13 subcutaneous administration at 50 mg / kg to cynomolgus monkeys. Graphs also show biomarkers levels during the 12-week recovery period for vehicle, 20 mg / kg IV and 50 mg / kg SC animals.
[0052] FIGS. 8A-8E shows dose dependent anti-TGF|33 antibody 2A10 treatment in a mouse bleomycin model of lung fibrosis. FIG. 8A shows a schematic for in vivo intratracheal bleomycin experiments. FIG. 8B shows a graph with clinical fibrosis scores in mouse lungs that were harvested 24 days after either saline (n=5) or bleomycin administration, with treatment by either isotype control (n=8) or anti-TGF[33 antibody 2A10 (n=8) (10 mg / kg; 3 times per weeks). FIGS. 8C-8E show graphs of whole-lung gene expression of Serpinel (FIG. 8C), Fnl (FIG. 8D), and Col lai (FIG. 8E) at day 14 following saline (n=5) or bleomycin installation. Animals were treated with either an isotype control (n=19) or anti- TGF|33 antibody 2A10. Doses of 2A10 were at lOmg / kg (n=20); 3mg / kg (n=19); Img / kg (n=19); 0.3mg / kg (n=18) or O. lmg / kg (n=20) once per week. *P < 0.05; **P < 0.01; ***p < 0.001; ****p < 0.0001; and NS, P>0.05 by one-way ANOVA with Dunnett’s test. Data represent means ± SEM.
[0053] FIG. 9 is a graph showing observed and model-predicted [median, 5thpercentile, 95thpercentile] concentration-time profiles for the anti-TGF[33 antibody R07303509 in a Phase I clinical trial following a single IV (50 mg, 1.06 h infusion) administration of anti- TGF[33 antibody R07303509 in healthy subjects. The insert is a graph of the first 14 days of observed and model-predicted [median, 5thpercentile, 95thpercentile] concentration-time profiles.
[0054] FIG. 10 is a schematic of a study design of an anti-TGF[33 antibody R07303509 single ascending dose study in healthy volunteers. IV refers to intravenous and SC refers to subcutaneous.
[0055] FIG. 11 is a table showing subject disposition (ITT Population) for Cohort A (50 mg IV anti-TGF[33 antibody R07303509 vs Placebo), Cohort B (150 mg IV anti-TGF[33 antibody R07303509 vs Placebo), Cohort C (240 mg IV anti-TGF[33 antibody R07303509 vs Placebo), Cohort D (240 mg SC anti-TGF[33 antibody R07303509 vs Placebo), Cohort E (675 mg SC anti-TGF[33 antibody R07303509 vs Placebo), Cohort F (1200 mg SC anti- TGFP3 antibody R07303509 vs Placebo), and all cohorts combined. IV refers to intravenous and SC refers to subcutaneous.
[0056] FIG. 12 is a table showing adverse events related to study treatment (safety evaluable) in Cohort C (240 mg IV anti-TGF[33 antibody R07303509 vs Placebo), Cohort F (1200 mg SC anti-TGF[33 antibody R07303509 vs Placebo), and Cohorts C and F combined. IV refers to intravenous and SC refers to subcutaneous.
[0057] FIG. 13 is a graph showing the mean (± SD) of anti-TGF[33 antibody R07303509 plasma concentration versus nominal time by treatment in linear scale (PK-evaluable population).
[0058] FIG. 14 is a graph showing the mean (± SD) of anti-TGF[33 antibody R07303509 plasma concentration versus nominal time by treatment in log scale (PK-evaluable population).
[0059] FIG. 15 is a dose-proportionality plot for maximum concentration versus dose for anti-TGFp3 antibody R07303509, subcutaneous cohorts (PK-evaluable population). SAD refers to single ascending dose. The scale is natural log for both x-axis and y-axis. The horizontal lines on the graph represent the median.
[0060] FIG. 16 is a dose-proportionality plot for AUCo-inf versus dose after single subcutaneous administration of anti-TGF[33 antibody R07303509 (PK-evaluable population). SAD refers to single ascending dose and inf refers to infinity. Scale is natural log for both x- axis and y-axis; horizontal lines, medians.
[0061] FIG. 17 is a dose-proportionality plot for AUCo-inf versus dose after single intravenous (IV) or subcutaneous administration of anti-TGF[33 antibody R07303509 (PK- evaluable population). SAD refers to single ascending dose and inf refers to infinity. Scale is natural log for both x-axis and y-axis; horizontal lines, medians. Subcutaneous doses were adjusted by the observed bioavailability of 73%.
[0062] FIGS. 18A-18B show graphs of the serum levels of Periostin and COMP after intravenous (FIG. 18A) or subcutaneous (FIG. 18B) administration of the anti-TGF[33 antibody R07303509 or placebo. H refers to hours post dose; pre, refers to predose; IV refers to intravenous; SC refers to subcutaneous; and SE refers to standard error.
[0063] FIG. 19 is the study schema for multiple-ascending dose administration of an anti- TGF[33 antibody R07303509 in subjects with systemic sclerosis, showing subjects enrolled in two stages: a double-blind, placebo-controlled MAD stage and an optional open-label safety extension (OSE) stage.
[0064] FIGS. 20A-20F are plots showing TGF[33 is upregulate and correlates with expression of TGF[3 target genes in systemic sclerosis skin (SSc) samples. FIG. 20A are violin plots showing gene expression as log2 normalized CPM of TGF[33 isoforms in control (n=14) and SSc skin (n=64) biopsies with individual sample points annotated according to TGF[33 signature score clustering and the black bars indicate the mean expression within each condition. FIG. 20B is a scatter plot showing the log2 fold-change for genes expressed in RNA-seq of in vitro human primary skin fibroblasts (y-axis) and skin biopsies (x-axis), withpositive log2 fold-change corresponding to upregulation in TGFP3 stimulated fibroblasts (compared to unstimulated) and SSc skin (compared to control skin), respectively. Gene names highlighted in black met filtering and selection criteria for inclusion in the TGFP signature gene set. FIG. 20C shows a row scaled heat map of the TGFP signature gene set expression in SSc and control skin biopsies, groups by hierarchical clustering of expression data into TGFP-High, -Mid and -Low classes (divided by white space). FIGS. 20D-20F shows a scatterplot and linear regression of TGFP isoform expression against TGFP signature score (eigengene) in SSc and control skin RNA-seq. 95% confidence interval about the dotted linear regression line is shown as a grey ribbon and points are colored according to the patient clusters defined in FIG. 20C.
[0065] FIGS. 21A-21D show that TGFP3 is expressed by disease-associated fibroblast populations in systemic sclerosis (SSc) skin. FIG. 21A is an annotated UMAP representation of combined control and SSc skin single-cell RNA sequencing data from GSE138669 (Tabib et al., “Myofibroblast transcriptome indicates SFRP2(hi) fibroblast progenitors in systemic sclerosis skin,” Nature Communications, 12: 4384 (2021)) highlighting population granularity in the mesenchymal compartment. FIG. 21B shows boxplots with the relative size of each cell population as a percent of total cells within each sample, separated into control (grey) and SSc (green). FIG. 21C shows a dot plot with normalized and scaled average expression level, indicated by color, and percent of cells expressing each gene (>1 UMI), indicated by dot size, for TGFP family ligands / receptors, skin TGFP signature genes, and cell type marker genes; shown is expression within SSc samples only. FIG. 21D is a box plot showing percent of cells expressing TGFP3 (>1 UMI) shown for each individual SSc sample as points, corresponding to the population aggregate percentage displayed as dot size in FIG. 21C.
[0066] FIGS. 22A-22D shows that TGFP skin signature score correlates with serum biomarker levels and prognosis in systemic sclerosis (SSc). FIG. 22A shows scatterplot and linear regression of serum COMP levels against TGFP signature score (eigengene), limited to SSc subjects with both serum protein and RNA-seq skin measurements (n=37). FIG. 22B shows scatterplot and linear regression of serum periostin levels against TGFP signature score (eigengene), limited to SSc subjects with both serum protein and RNA-seq skin measurements (n=37). FIG. 22C shows baseline mRSS score at 48 weeks against the TGFP signature score, limited to SSc patients with both 48-week mRSS scores and RNA-seq skin measurements (n=34). FIG. 22D shows percent change in mRSS score at 48 weeks against the TGFP signature score, limited to SSc patients with both 48-week mRSS scores and RNA-seq skin measurements (n=34). In FIGS. 22A-22D, 95% confidence interval about the dotted linear regression line is shown as a grey ribbon and sample clustering is denoted by point color and the violin plots on the right are separated by the same sample clustering shown on the left plots.
[0067] FIG. 23 shows serum biomarker levels of COMP and periostin are correlated with mRSS scores. FIG. 23 shows scatterplot and linear regression of serum COMP (Panel A) or periostin (Panel B) levels against baseline mRSS score in the faSScinate trial, limited to systemic sclerosis (SSc) subjects with both serum protein and RNA-seq skin measurements (n=67 for COMP excluding 1 outlier, n=61 for periostin); 95% confidence interval about the dotted linear regression line is shown as a grey ribbon. Pearson correlation and 95% CI are denoted in the upper left of each plot.DETAILED DESCRIPTIONGeneral
[0068] Practice of the methods, as well as preparation and use of the compositions disclosed herein employ, unless otherwise indicated, conventional techniques in molecular biology, biochemistry, chromatin structure and analysis, computational chemistry, cell culture, recombinant DNA and related fields as are within the skill of the art. These techniques are fully explained in the literature. See, for example, Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL, Fourth edition, Cold Spring Harbor Laboratory Press, 2012; Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987-2010 and other like references.
[0069] The term “herein” means the entire disclosure.
[0070] It should be understood that any of the embodiments described herein, including those described under different aspects of the disclosure and different parts of the specification (including embodiments described only in the Examples) can be combined with one or more other embodiments disclosed herein, unless explicitly disclaimed or improper. Combinations of embodiments are not limited to those specific combinations claimed via the multiple dependent claims.
[0071] Any publications, patents and published patent applications referred to in this disclosure are specifically incorporated by reference herein. In case of conflict, the present specification, including its specific definitions, will control.
[0072] Throughout this specification, the word “comprise” or variations such as “comprises” or “comprising,” which is synonymous with “including,” “containing,” or“characterized by,” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.
[0073] Throughout the specification, where compositions are described as having, including, or comprising (or variations thereof), specific components, it is contemplated that compositions also may consist essentially of, or consist of, the recited components.Similarly, where methods or processes are described as having, including, or comprising specific process steps, the processes also may consist essentially of, or consist of, the recited processing steps. Further, it should be understood that, unless otherwise indicated or the context clearly indicates otherwise, the order of steps or order for performing certain actions is immaterial so long as the Compositions and methods described herein remains operable. Moreover, two or more steps or actions can be conducted simultaneously.
[0074] The term “consisting of’ excludes any element, step, or ingredient not specifically recited.
[0075] The term “consisting essentially of’ limits the scope of a disclosure to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s) of the disclosure.
[0076] Any example(s) following the term “e.g.” or “for example” is not meant to be exhaustive or limiting.
[0077] The articles “a,” “an” and “the” are used herein to refer to one or to more than one (z.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.
[0078] As used herein, the term “about” modifying the quantity of an ingredient, parameter, calculation, or measurement in the compositions employed in the methods of the disclosure refers to the variation in the numerical quantity that can occur, for example, through typical measuring and liquid handling procedures used for making isolated polypeptides or pharmaceutical compositions in the real world; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of the ingredients employed to make the compositions or carry out the methods; and the like without having a substantial effect on the chemical or physical attributes of the compositions or methods of the disclosure. Such variation can be within 5%, of a given value or range. The term “about” also encompasses amounts that differ due to different equilibrium conditions for a composition resulting from a particular initial mixture. Whether or not modified by the term “about,” the paragraphs include equivalents to the quantities. Reference to “about” a value or parameter herein includes (and describes) in particular embodiments that are directed to that value orparameter per se. For example, description referring to “about X” includes description of “X.” Numeric ranges are inclusive of the numbers defining the range.
[0079] The term “or” as used herein should be understood to mean “and / or,” unless the context clearly indicates otherwise.
[0080] Where used herein, “and / or” is to be taken as specific disclosure of each of the two specified features or components with or without the other. For example “A and / or B” is to be taken as specific disclosure of each of (i) A, (ii) B and (iii) A and B, just as if each is set out individually herein.
[0081] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the disclosure are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. Also, recitations of numerical values are not limited to specifically the recited value, but also include numbers that the skilled artisan would normally round to that value in the context of significant digits. Moreover, all ranges disclosed herein are to be understood to encompass any and all subranges subsumed therein. For example, a stated range of “1 to 10” should be considered to include any and all subranges between (and inclusive of) the minimum value of 1 and the maximum value of 10; that is, all subranges beginning with a minimum value of 1 or more, e.g., 1 to 6.1, and ending with a maximum value of 10 or less, e.g., 5.5 to 10. The disclosure of a range should also be considered as disclosure of the endpoints of that range.
[0082] Exemplary methods and materials are described herein, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure. The materials, methods, and examples are illustrative only and not intended to be limiting.Definitions
[0083] The following terms, unless otherwise indicated, shall be understood to have the following meanings:
[0084] The term “acceptor human framework” for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor humanframework “derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence. In some embodiments, the VH acceptor human framework is identical in sequence to the VH human immunoglobulin framework sequence or human consensus framework sequence.
[0085] The terms “administering” or “administration of’ a substance, a compound, an agent, an antibody, or a composition to a subject, as used herein, refers to the contact of that substance, compound, agent, an antibody, or composition to the subject or a cell, tissue, organ or bodily fluid of the subject. Such administration can be carried out using one of a variety of methods known to those skilled in the art. For example, a substance, compound, agent, an antibody, or composition can be administered parenterally, such as by injection. In some embodiments, a substance, compound, agent, antibody, or composition is administered subcutaneously. In some embodiments, a substance, compound, agent, antibody, or composition is administered intravenously. Administering can also be performed, for example, once, a plurality of times, and / or over one or more extended periods. In some embodiments, the administration includes both direct administration, including selfadministration, and indirect administration, including the act of prescribing a drug. For example, as used herein, a physician who instructs a subject to self-administer a drug, or to have the drug administered by another and / or who provides a subject with a prescription for a drug is administering the drug to the subject.
[0086] As used herein, the term “antibody” or “Ab” is used in the broadest sense and includes monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, and multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.
[0087] The term “antibody fragment” as used herein refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.
[0088] The terms “anti-transforming growth factor beta 3 antibody,” anti-transforming growth factor beta 3 monoclonal antibody,” “anti-TGF[33 antibody,” “anti-TGF[33monoclonal antibody,” and “an antibody that specifically binds to TGFP3” are used interchangeably herein and refer to an antibody that is capable of binding TGFP3 with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent in targeting TGFP3. In some embodiments, the extent of binding of an anti-TGFp3 antibody to an unrelated, non-TGFp3 protein is less than about 10% of the binding of the antibody to TGFP3 as measured, e.g., by a radioimmunoassay (RIA). In certain embodiments, an antibody that binds to TGFP3 has a dissociation constant (Kd) of < IpM, < 100 nM, < 10 nM, < 1 nM, < 0.1 nM, < 0.01 nM, or < 0.001 nM (e.g., 10'8M or less, e.g., from 10'8M to 10"13M, e.g., from 10'9M to 10'13M).
[0089] The term “chimeric” antibody as used herein refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.
[0090] The term “class” of an antibody as used herein refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGi, IgG2, IgGs, IgG4, IgAi, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called a, 5, a, y, and p, respectively.
[0091] As used herein, the term “cycle” refers to each administration event in a series of regularly repeated administration steps. For example, if a therapeutic agent (e.g., a heterodimeric protein of the present disclosure) is administered once every two weeks (Q2W), the first cycle begins on day 1 and ends on day 14, the second cycle begins on day 15 and ends on day 28, the third cycle begins on day 29 and ends on day 42, and so on. Measurements may be taken, and combination therapies may be administered, mid-cycle. Mid-cycle events can be defined by the cycle and the day in the cycle in which they occur, e.g., a measurement taken one week into a two-week cycle might be numbered Cycle 1, Day 8 (or C1D8). For combination therapies, a cycle will be defined by the period in which it takes the administration pattern to repeat. For example, if a first therapeutic agent is administered Q2W and a second therapeutic agent is administered Q1W, then the cycle is a two-week cycle. In such a case, if both agents are administered on CID 1, then the second dose of the second agent would be administered on C1D8, and the second dose of the first agent combined with the third dose of the second agent would be administered one week later to start the second cycle (i.e., C2D1). If a first therapeutic agent is administered Q1W and a second therapeutic agent is administered every three days (Q3D), then it will take threeweeks for the administration pattern to repeat, so the cycle would be a three-week cycle and would include 3 administrations of the first agent and seven administrations of the second agent. For example, 3 cycles administered at a frequency of Q4W refers to administering the composition every four weeks for 3 times.
[0092] An “effective amount” of an agent, e.g., a pharmaceutical formulation or composition, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. The term “therapeutically effective amount” refers to an amount of, e.g., an agent (such as an antibody as described elsewhere herein, or composition effective for therapeutic treatment of a disease or disorder in a subject (e.g., a mammal, such as a human). The term “prophylactically effective amount” refers to an amount of, e.g., an agent (such as an antibody as described elsewhere herein, or composition effective for prophylactic treatment of a disease or disorder in a subject (e.g., a mammal, such as a human). A therapeutically effective or prophylactically effective amount herein may vary according to factors such as the disease state, age, sex, and weight of the patient, and the ability of the substance, compound, agent or composition, such as an antibody, to elicit a desired response in the individual. The appropriate amount and dosage regimen can be determined using routine skill in the art. A therapeutically effective amount or prophylactically effective amount can be administered in one or more administrations. For purposes of this disclosure, a therapeutically effective amount or prophylactically effective amount of drug, compound, or pharmaceutical composition is an amount sufficient to accomplish therapeutic treatment either directly or indirectly.
[0093] As used herein, the term “effector function” refers to a biological activity attributable to the Fc region of an antibody, which varies with the antibody isotype. Examples of antibody effector functions include: Clq binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor); and B cell activation. The term “ADCC” or “antibody dependent cell-mediated cytotoxicity,” as used herein, refers to the cell-mediated reaction wherein nonspecific cytotoxic cells that express FcyRs recognize bound antibody on a target cell and subsequently cause lysis of the target cell. ADCC is correlated with binding to FcyRIIIa; increased binding to FcyRIIIa leads to an increase in ADCC activity. The term “ADCP” or “antibody dependent cell-mediated phagocytosis,” as used herein, refers to the cell-mediated reaction wherein nonspecific cytotoxic cells that express FcyRs recognize bound antibody on a target cell and subsequently cause phagocytosis of the target cell. The term “CDC” or “complement-dependent cellularcytotoxicity,” as used herein, refers to an effector function which leads to the activation of the classical complement pathway, which is triggered by the binding of an antibody to an antigen on the target cell, which activates a series of cascades containing complement-related protein groups in blood.
[0094] The terms “Fc,” “Fc region” or “Fc domain” are used interchangeably herein and refer to a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5thEd. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
[0095] As used herein, the terms “Fc fusion protein” and “immunoadhesin” are used interchangeably and refer to a protein comprising an Fc region, generally linked (optionally through a linker moiety, as described herein) to a different protein, such as to IL- 15 and / or IL-15R, as described herein. In some instances, two Fc fusion proteins can form a homodimeric Fc fusion protein or a heterodimeric Fc fusion protein with the latter being preferred.
[0096] As used herein, the term “Fc variant” or “variant Fc” refers to a protein comprising an amino acid modification in an Fc domain. The Fc variants of the present invention are defined according to the amino acid modifications that compose them. Thus, for example, N434S or 434S is an Fc variant with the substitution serine at position 434 relative to the parent Fc polypeptide, wherein the numbering is according to the EU index. Likewise, M428L / N434S defines an Fc variant with the substitutions M428L and N434S relative to the parent Fc polypeptide. For all positions discussed in the present invention that relate to antibodies, unless otherwise noted, amino acid position numbering is according to the EU index. The modification can be an addition, deletion, or substitution. Substitutions can include naturally occurring amino acids and, in some cases, synthetic amino acids. Examples include, but are not limited to, U.S. Pat. No. 6,586,207; WO 98 / 48032; WO 03 / 073238; US2004-0214988A1; WO 05 / 35727A2; WO 05 / 74524A2; J. W. Chin et al., (2002), Journal of the American Chemical Society 124:9026-9027; J. W. Chin, & P. G. Schultz, (2002), ChemBioChem 11 : 1135-1137; J. W. Chin, et al., (2002), PICAS United States of America99: 11020-11024; and, L. Wang, & P. G. Schultz, (2002), Chem. 1-10, all of them entirely incorporated by reference. In some embodiments, the substitutions comprise only naturally occurring amino acids. In some embodiments, the substitutions do not comprise any synthetic amino acids.
[0097] The terms “Fc gamma receptor,” “FcyR” and “FcgammaR,” as used herein, are used interchangeably and refer to any member of the family of proteins that bind the IgG antibody Fc region and is encoded by an FcyR gene. An FcyR may be from any organism. In some embodiments, the FcyR is a human FcyR. In humans this family includes but is not limited to FcyRI (CD64), including isoforms FcyRIa, FcyRIb, and FcyRIc; FcyRII (CD32), including isoforms FcyRIIa (including allotypes H131 and R131), FcyRIIb (including FcyRIIb-1 and FcyRIIb-2), and FcyRIIc; and FcyRIII (CD16), including isoforms FcyRIIIa (including allotypes V158 and F158) and FcyRIIIb (including allotypes FcyRIib-NAl and FcyRIIb- NA2) (Jefferis et al., 2002, Immunol Lett 82:57-65, entirely incorporated by reference), as well as any undiscovered human FcyRs or FcyR isoforms or allotypes.
[0098] The term “FcRn” or “neonatal Fc Receptor,” as used herein, refers to a protein that binds the IgG antibody Fc region and is encoded at least in part by an FcRn gene. The FcRn may be from any organism. In some embodiments, the FcRn is a human FcRn. As is known in the art, the functional FcRn protein comprises two polypeptides, often referred to as the heavy chain and light chain. The light chain is beta-2-microglobulin and the heavy chain is encoded by the FcRn gene. Unless otherwise noted herein, FcRn or an FcRn protein refers to the complex of FcRn heavy chain with beta-2 -microglobulin. A variety of FcRn variants can be used to increase binding to the FcRn receptor, and in some cases, to increase serum halflife. In general, unless otherwise noted, the Fc monomers disclosed herein retain binding to the FcRn receptor (and, as noted below, can include amino acid variants to increase binding to the FcRn receptor).
[0099] The term “framework” or “FR” as used herein refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2- H2(L2)-FR3-H3(L3)-FR4.
[0100] The terms “full-length antibody,” “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
[0101] The term “human antibody” as used herein refers to an antibody that possesses an amino-acid sequence which corresponds to that of an antibody produced by a human, a human cell, derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences and / or has been made using any of the techniques known in the art for making human antibodies. A “human antibody” specifically excludes a humanized antibody comprising non-human antigen-binding residues. Human antibodies can be produced using various techniques known in the art, including phage-display libraries, mouse hybridoma, transgenic animals (e.g., mice) and single B cell technique. See, e.g., Lu et al, J. Biomed. Sci., 27: 1 (2020); Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991), each of which is incorporated by reference herein in its entirety. Also available for the preparation of human monoclonal antibodies are methods described in Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner et al., J. Immunol., 147(1): 86-95 (1991). See also van Dijk and van de Winkel, Curr. Opin. Pharmacol., 5: 368-74 (2001). Human antibodies can be prepared by administering the antigen to a transgenic animal that has been modified to produce human antibodies in response to antigenic challenge, e.g., immunized xenomice (see, e.g., U.S. Pat. Nos. 6,075,181 and 6,150,584 regarding XENOMOUSE™ technology). Other transgenic animals for producing human antibodies are also known in the art, including, e.g., the HuMAb mouse, the UntiMAb mouse, the Transchromo mouse, the Veloclmmune mice, the OmniRat, the OmniMouse, the Harbour Mouse, the Kymouse, the MeMo mouse, the AlivaMab mouse, etc. See, e.g., Bruggemann et al., Arch. Immunol. Ther. Exp. (Warsz.) 2015, vol. 63(2): 101-108. Additional techniques are also known the art. See also, for example, Li et al., Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006) regarding human antibodies generated via a human B-cell hybridoma technology.
[0102] The term “human consensus framework” as used herein refers to a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda Md. (1991), vols. 1-3. In one embodiment, for the VL, the subgroup is subgroup kappa I as in Kabat et al., supra. In one embodiment, for the VH, the subgroup is subgroup III as in Kabat et al., supra.
[0103] The term “humanized” antibody, as used herein, refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from humanFRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A “humanized form” of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization. For example, humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, certain framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. The humanized antibody, optionally, will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al, Nature 321 :522-525 (1986); Riechmann et al, Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992). See also, Vaswani and Hamilton, Ann. Allergy, Asthma & Immunol. 1 : 105-115 (1998); Harris, Biochem. Soc. Transactions 23 : 1035-1038 (1995); Hurle and Gross, Curr. Op. Biotech. 5:428-433 (1994).
[0104] The terms “hypervariable region,” “HVR,” or “HV,” are used interchangeably herein and refer to each of the regions of an antibody variable domain which are hypervariable in sequence (“complementarity determining regions” or “CDRs”) and / or form structurally defined loops (“hypervariable loops”) and / or contain the antigen-contacting residues (“antigen contacts”). Generally, antibodies comprise six HVRs (e.g., CDRs): three in the VH (Hl, H2, H3), and three in the VL (LI, L2, L3).In native antibodies, H3 and L3 display the most diversity of the six HVRs, and H3, in particular, is believed to play a unique role in conferring fine specificity to antibodies. See, e.g., Xu et ah, Immunity 13:37-45 (2000); Johnson and Wu, Methods in Molecular Biology 248: 1-25 (Lo, ed., Human Press, Totowa, NJ, 2003). For example, naturally occurring camelid antibodies consisting of only a heavy chain are functional and stable in the absence of light chain. See, e.g., Hamers-Casterman et al, Nature 363:446- 448 (1993); Sheriff et al, Nature Struct. Biol. 3:733-736 (1996). Exemplary HVRs herein include:(a) hypervariable loops occurring at amino acid residues 26-32 (LI), 50-52 (L2), 91- 96 (L3), 26-32 (Hl), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901- 917 (1987));(b) CDRs occurring at amino acid residues 24-34 (LI), 50-56 (L2), 89-97 (L3), 31- 35b (Hl), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5thEd. Public Health Service, National Institutes of Health, Bethesda, MD (1991));(c) antigen contacts occurring at amino acid residues 27c-36 (LI), 46-55 (L2), 89-96 (L3), 30-35b (Hl), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262: 732- 745 (1996)); and(d) combinations of (a), (b), and / or (c), including HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (Hl), 26-35b (Hl), 49-65 (H2), 93-102 (H3), and 94-102 (H3).
[0105] Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., supra.
[0106] A number of HVR delineations are used in the art and are encompassed herein. The Kabat Complementarity Determining Regions (CDRs) are based on sequence variability and are one of the most commonly used definitions (Kabat et al., Sequences of Proteins of Immunological Interest, 5thEd. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). Chothia refers, instead, to the location of the structural loops (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)). The AbM HVRs represent a compromise between the Kabat HVRs and Chothia structural loops and are used by Oxford Molecular’s AbM antibody modeling software. The “contact” HVRs are based on an analysis of the available complex crystal structures. The IMGT numbering system was created by taking into account the high conservation of the structure of the V domain and by integrating the knowledge acquired by the analysis of multiple sources: alignment of more than 5000 sequences, literature data on the framework (FR) and complementarity determining regions (CDR), structural data from X-ray diffraction studies and characterization of the CDR hypervariable loops. The residues from each of these HVRs are noted below in Table 1.Table 1.
[0107] Unless otherwise indicated, the HVRs are determined according to Kabat et al., supra. HVRs may comprise “extended HVRs” as follows: residues 24-36 or 24-34 (LI), residues 46-56 or 50-56 (L2) and residues 89-97 or 89-96 (L3) in the VL and residues 26-35 (Hl), residues 50-65 or 49-65 (H2) and residues 93-102, 94-102, or 95-102 (H3) in the VH, each according to Kabat numbering.
[0108] The term “immunoconjugate” as used herein refers to an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.
[0109] The term “isolated” antibody as used herein refers to an antibody which has been separated from a component of its natural environment. In some embodiments, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC). For review of methods for assessment of antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).
[0110] The term “isolated” nucleic acid as used herein refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
[0111] The term “isolated nucleic acid encoding an anti-TGF[33 antibody” as used herein refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.
[0112] The term “modification,” as used herein, refers to an amino acid substitution, insertion, and / or deletion in a polypeptide sequence or an alteration to a moiety chemicallylinked to a protein. For example, a modification may be an altered carbohydrate or PEG structure attached to a protein. By “amino acid modification” herein is meant an amino acid substitution, insertion, and / or deletion in a polypeptide sequence. For clarity, unless otherwise noted, the amino acid modification is always referring to an amino acid coded for by DNA, e.g., the 20 amino acids that have codons in DNA and RNA.
[0113] The term “monoclonal antibody,” as used herein, refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and / or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.
[0114] The term “naked antibody” as used herein refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present in a pharmaceutical formulation.
[0115] The term “native antibody” as used herein refers to a naturally occurring immunoglobulin molecule with varying structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 Daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CHI, CH2, and CH3).Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody may be assigned to one of two types, called kappa (K) and lambda (X), based on the amino acid sequence of its constant domain.
[0116] The terms “nucleic acid,” “polynucleotide” and “oligonucleotide” are used interchangeably and refer to a deoxyribonucleotide or ribonucleotide polymer, in linear or circular conformation, and in either single- or double-stranded form. For the purposes of the present disclosure, these terms are not to be construed as limiting with respect to the length of a polymer. The terms can encompass known analogues of natural nucleotides, as well as nucleotides that are modified in the base, sugar and / or phosphate moieties (e.g., phosphorothioate backbones). In general, an analogue of a particular nucleotide has the same base-pairing specificity; i.e., an analogue of A will base-pair with T. In some embodiments, the polynucleotide comprises only natural nucleotides. In some embodiments, the polynucleotide does not comprise any analogues of a natural nucleotide.
[0117] The term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and / or warnings concerning the use of such therapeutic products.
[0118] As used herein, “percent (%) amino acid sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary. In situations where ALIGN-2 is employed for aminoacid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X / Y, where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program’s alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program (see, e.g., paragraphs
[0279] to
[0280] of US Pub. No. 20160244525, hereby incorporated by reference).
[0119] The terms “polypeptide,” “peptide” and “protein” are used interchangeably to refer to a polymer of amino acid residues. The term also applies to amino acid polymers in which one or more amino acids are chemical analogues or modified derivatives of a corresponding naturally-occurring amino acids. In some embodiments, the polypeptide only comprises naturally-occurring amino acids. In some embodiments, the polypeptide does not comprise any chemical analogues or modified derivatives of a corresponding naturally-occurring amino acids. Expression of a fusion protein in a cell can result from delivery of the fusion protein to the cell or by delivery of a polynucleotide encoding the fusion protein to a cell, wherein the polynucleotide is transcribed, and the transcript is translated, to generate the fusion protein. Trans-splicing, polypeptide cleavage and polypeptide ligation can also be involved in expression of a protein in a cell. Methods for polynucleotide and polypeptide delivery to cells are known in the art.
[0120] The term “position,” as used herein, refers to a location in the sequence of a protein. Positions may be numbered sequentially, or according to an established format, for example the EU index for antibody numbering. A position may be defined relative to a reference sequence. In such cases, the reference sequence is provided for comparison purposes, and the heterodimeric protein of the disclosure (or a portion thereof) may comprise additional amino acid alterations (e.g., substitutions, insertions, and deletions) relative to the reference sequence. In some embodiments, the heterodimeric protein of the disclosure (or a portion thereof) does not comprise any additional amino acid alterations relative to the reference sequence.
[0121] The terms “patient,” “subject” and “individual” are used interchangeably herein and refer to either a human or a non-human animal in need of treatment. These terms include mammals. Mammals include, but are not limited to, primates (e.g., humans, and non-human primates such as monkeys,), domesticated animals (e.g., cows, sheep, cats, dogs, and horses), rabbits, and rodents (e.g., mice and rats). In some embodiments, the subject is a human. In some embodiments, the subject is a human who was previously diagnosed with systemic sclerosis and / or received a treatment. In some embodiments, the subject is a human who was previously diagnosed with systemic sclerosis and did not receive a treatment for that.
[0122] The term “pharmaceutical formulation” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
[0123] A “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
[0124] The terms “residue” and “amino acid residue” are used interchangeably herein and refers to a position in a protein and its associated amino acid identity. For example, Asparagine 297 (also referred to as Asn297 or N297) is a residue at position 297 in a specific protein.
[0125] As used herein, “treatment” (and grammatical variations thereof such as “treat” or “treating”) refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis (prophylactic treatment) or during the course of clinical pathology (therapeutic treatment). Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antibodies of the invention are used to delay development of a disease or to slow the progression of a disease.
[0126] The terms “transforming growth factor [33” and “TGF[33” are used interchangeably and refer to any native TGF[33 isoform from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated. The term encompasses “full-length,” unprocessed TGF[33 as well as any form of TGF[33 thatresults from processing in the cell. The term also encompasses naturally occurring variants of TGFP3, e.g., splice variants or allelic variants. TGFP3 isoforms have precursor forms (immature) and mature forms. The amino acid sequence of an exemplary human TGFP3 is as follows:Human TGFB3MKMHLQRALVVL ALLNF ATVSLSLSTCTTLDFGHIKKKRVEAIRGQILSKLRLTSPPE PTVMTHVPYQVLALYNSTRELLEEMHGEREEGCTQENTESEYYAKEIHKFDMIQGL AEHNELAVCPI<GITSI<VFRFNVSSVEI<NRTNLFRAEFRVLRVPNPSSI<RNEQRIELFQI LRPDEHIAKQRYIGGKNLPTRGTAEWLSFDVTDTVREWLLRRESNLGLEISIHCPCHT FQPNGDILENIHEVMEIKFKGVDNEDDHGRGDLGRLKKQKDHHNPHLILMMIPPHRL DNPGQGGQRKKRALDTNYCFRNLEENCCVRPLYIDFRQDLGWKWVHEPKGYYANF CSGPCPYLRSADTTHSTVLGLYNTLNPEASASPCCVPQDLEPLTILYYVGRTPKVEQL SNMVVKSCKCS (SEQ ID NO: 12).
[0127] The term “variable region” or “variable domain,” as used herein, refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindt et al. Kuby Immunology, 6thed., W.H. Freeman and Co., page 91 (2007).) While a VH domain is typically paired with a VL domain, a single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al, J. Immunol. 150 : 880-887 (1993) ; Clarkson et al, Nature 352 : 624-628 (1991).
[0128] The terms “wild type” or “WT” are used interchangeably herein and refer to an amino acid sequence or a nucleotide sequence that is found in nature, including allelic variations. A WT protein has an amino acid sequence or is encoded by a nucleotide sequence that has not been intentionally modified.
[0129] As used herein, the term “gene signature” is used interchangeably with “gene expression signature” and refers to one or a combination of genes whose expression is indicative of a subject or tissue or other sample isolated from a subject having high TGFp activity and / or indicative of a subject being likely to benefit from treatment with an inhibitor of a TGFp isoform characterized by certain molecular, pathological, histological,radiographic and / or clinical features. In certain embodiments, the expression of one or more genes comprising the gene signature is elevated compared to that in control subjects.
[0130] As used herein, the term “elevated expression level” or “elevated levels” refers to an increased expression of a mRNA or a protein in a subject (e.g., a subject, e.g., a patient, suspected of having or diagnosed as having a TGFP-related disorder, e.g, fibrosis, e.g, Progressive Fibrotic Interstitial Lung Diseases (PF-ILD) (e.g., SSc)) relative to a control, such as an individual or individuals who are not suffering from the TGFP-related disorder.
[0131] As used herein, the term “sample” refers to a composition that is obtained or derived from a subject of interest that contains a cellular and / or other molecular entity that is to be characterized and / or identified, for example based on physical, biochemical, chemical and / or physiological characteristics. For example, the phrase “disease sample” and variations thereof refers to any sample obtained from a subject of interest that would be expected or is known to contain the cellular and / or molecular entity that is to be characterized. In some embodiments, the sample is whole blood. In some embodiments, the sample is plasma. In some embodiments, the sample is serum.
[0132] By “tissue” or “cell sample” is meant a collection of similar cells obtained from a tissue of a subject or patient. The source of the tissue or cell sample may be solid tissue as from a fresh, frozen and / or preserved organ or tissue sample or biopsy or aspirate; blood or any blood constituents; bodily fluids such as cerebral spinal fluid, amniotic fluid, peritoneal fluid, or interstitial fluid; cells from any time in gestation or development of the subject. The tissue sample may also be primary or cultured cells or cell lines. Optionally, the tissue or cell sample is obtained from a disease tissue / organ. The tissue sample may contain compounds which are not naturally intermixed with the tissue in nature such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, or the like. A “reference sample”, “reference cell”, “reference tissue”, “control sample”, “control cell”, or “control tissue”, as used herein, refers to a sample, cell or tissue obtained from a source known, or believed, not to be afflicted with the disease or condition for which a method or composition of the invention is being used to identify. In one embodiment, a reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from a healthy part of the body of the same subject or patient in whom a disease or condition is being identified using a composition or method of the invention. In one embodiment, a reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from a healthy part of the body of an individual who is not the subject or patient in whom a disease or condition is being identified using a composition or method of the invention.Overview
[0133] The present disclosure relates to methods of treating a TGFP-related disorder in a subject comprising administering to the subject a therapeutically effective amount of an anti-TGF|33 antibody. In some embodiments, the TGFP-related disorder is fibrosis (e.g., fibrotic condition of the lung, liver, heart, kidney, pancreas, eye, and / or skin). In some embodiments, the fibrosis incudes but is not limited to systemic sclerosis, idiopathic pulmonary fibrosis (IPF) and progressive fibrotic interstitial lung disease (PF-ILD).
[0134] In some embodiments, the disclosure relates to methods of treating systemic sclerosis in a subject comprising administering to the subject a therapeutically effective amount of an anti-TGFp3 antibody. Systemic sclerosis (SSc) (also referred to as scleroderma) is a complex and heterogeneous disease with skin and tissue fibrosis, vascular alterations, and autoantibodies against various cellular antigens being amongst its principal features. The clinical manifestations of systemic sclerosis can range from limited skin involvement to severe internal organ dysfunction. Internal visceral organ pathology is a major factor contributing to the morbidity of this disease, with the kidneys, esophagus, heart, and lungs being the most frequently involved. There are two major subgroups in the commonly accepted classification of SSc: limited cutaneous SSc (IcSSc) and diffuse cutaneous SSc (dcSSc). Gabrielli et al. Mechanisms of disease. Scleroderma. N Engl J Med 360: 1989-2003 (2009). In some embodiments, the patient with systemic sclerosis has been classified according to the American College of Rheumatology (formerly, the American Rheumatism Association) criteria for the classification of systemic scleroderma based on: (a) major criterion: diffuse (truncal) sclerosis (skin tightness, thickening, and non-pitting induration); and (b) minor criteria: (1) sclerodactyly (only fingers and / or toes), (2) digital pitting scars or loss of substance of the digital finger pads (pulp loss), and (3) bilateral basilar pulmonary fibrosis, wherein a patient with systemic sclerosis should fulfill the major criterion or two of the three minor criteria. See Subcommittee for Scleroderma Criteria of the American Rheumatism Association, Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-90 (1980).
[0135] The present disclosure also relates to methods of inhibiting binding of TGFP3 to TGFBR2 in a subject comprising administering to the subject a therapeutically effective amount of an anti-TGF[33 antibody.Anli-T(jI- / 'J>3 antibodies
[0136] In any of the aspects disclosed herein, the anti -transforming growth factor beta 3 (TGF|33) antibody comprises a) a heavy chain variable region (VH) comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region (VL) comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0137] In some embodiments, the anti-TGF[33 antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 7. In some embodiments, the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7. In some embodiments, the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 7. In some embodiments, the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7.
[0138] In some embodiments, the anti-TGFp3 antibody comprises a light chain variable region (VL) comprising an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the anti-TGFp3 antibody comprises a light chain variable region (VL) comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the anti-TGFp3 antibody comprises a light chain variable region (VL) comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the anti-TGFp3 antibody comprises a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0139] In some embodiments, the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprises an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 7; and alight chain variable region (VL) comprises an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7; and a light chain variable region (VL) comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 7; and a light chain variable region (VL) comprises an amino acid sequence having at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 8. In some embodiments, the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprises the amino acid sequence of SEQ ID NO: 7; and a light chain variable region (VL) comprises to the amino acid sequence of SEQ ID NO: 8.
[0140] In some embodiments, the anti-TGFp3 antibody comprises a heavy (H) chain comprising an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 9. In some embodiments, the anti-TGFp3 antibody comprises a heavy (H) chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9. In some embodiments, the anti-TGFp3 antibody comprises a heavy (H) chain comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 9. In some embodiments, the anti-TGFp3 antibody comprises a heavy (H) chain comprising the amino acid sequence of SEQ ID NO: 9.
[0141] In some embodiments, the anti-TGFp3 antibody comprises a light (L) chain comprising an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 10. In some embodiments, the anti-TGFp3 antibody comprises a light (L) chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10. In some embodiments, the anti-TGFp3 antibody comprises a light (L) chain comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 10. In some embodiments, the anti-TGFp3 antibody comprises a light (L) chain comprising the amino acid sequence of SEQ ID NO: 10.
[0142] In some embodiments, the anti-TGF|33 antibody comprises (a) a heavy (H) chain comprising an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 9; and (b) a light (L) chain comprising an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 100% sequence identity to the amino acid sequence of SEQ ID NO: 10. In some embodiments, the anti-TGFp3 antibody comprises (a) a heavy (H) chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9; and (b) a light (L) chain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10. In some embodiments, the anti-TGFp3 antibody comprises (a) a heavy (H) chain comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 9; and (b) a light (L) chain comprising an amino acid sequence having at least 98% sequence identity to the amino acid sequence of SEQ ID NO: 10. In some embodiments, the anti-TGFp3 antibody comprises (a) a heavy (H) chain comprising the amino acid sequence of SEQ ID NO: 9; and (b) a light (L) chain comprising the amino acid sequence of SEQ ID NO: 10.
[0143] Specific anti-TGFp3 antibody sequences are provided in Table 2.Table 2: Amino acid sequences.
[0144] In some embodiments, the anti-TGF[33 antibody is h2A10.v4. The anti-TGF[33 antibody h2A10.v4 is also referred to herein as R07303509 or MTBT1466A. Anti-TGF[33 antibody h2A10.v4 (including the CDRs, VH, VL, heavy chain and light chain sequences) and its preparation is disclosed in US2021 / 0301005, the entire disclosure of which is incorporated by reference herein.
[0145] The heavy and light chain CDR amino acid sequences of anti-TGF[33 antibody h2A10.v4 are provided in Table 3.Table 3
[0146] The heavy and light chain variable region amino acid sequences of anti-TGF[33 antibody h2A10.v4 are provided in Table 4.Table 4
[0147] The heavy and light chain amino acid sequences of anti-TGF|33 antibody h2A10.v4 are provided in Table 5. Table 5
[0148] In some embodiments, the anti-TGF[33 antibody is a monoclonal antibody, a humanized antibody, or a chimeric antibody. In some embodiments, the anti-TGFp3 antibody is a monoclonal antibody. In some embodiments, the anti-TGFp3 antibody is a humanized antibody. In some embodiments, the anti-TGFp3 antibody is a chimeric antibody
[0149] In certain embodiments, an antibody provided herein is a chimeric antibody.Certain chimeric antibodies are described, e.g., in U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81 :6851-6855 (1984)). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region. In a further example, a chimeric antibody is a “class switched” antibody in which the class orsubclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
[0150] In certain embodiments, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which HVRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences. A humanized antibody optionally will also comprise at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.
[0151] Humanized antibodies and methods of making them are reviewed, e.g., in Almagro and Fransson, Front. Biosci. 13: 1619-1633 (2008), and are further described, e.g., in Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat’l Acad. Sci. USA 86: 10029-10033 (1989); US Patent Nos. 5, 821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describing specificity determining region (SDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describing “resurfacing”); Dall’Acqua et al., Methods 36:43-60 (2005) (describing “FR shuffling”); and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000) (describing the “guided selection” approach to FR shuffling).
[0152] Human framework regions that may be used for humanization include but are not limited to: framework regions selected using the “best-fit” method (see, e.g., Sims et al. J. Immunol. 151 :2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al. J. Immunol., 151 :2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13: 1619-1633 (2008)); and framework regions derived from screening FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272: 10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271 :22611-22618 (1996)).
[0153] In certain embodiments, an antibody provided herein is a human antibody. Human antibodies can be produced using various techniques known in the art. Human antibodies aredescribed generally in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).
[0154] Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal’s chromosomes. In such transgenic mice, the endogenous immunoglobulin loci have generally been inactivated. For review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23: 1117-1125 (2005). See also, e.g., U.S. Patent Nos. 6,075,181 and 6,150,584 describing XENOMOUSETM technology; U.S. Patent No. 5,770,429 describing HUMAB® technology; U.S. Patent No. 7,041,870 describing K-M MOUSE® technology, and U.S. Patent Application Publication No. US 2007 / 0061900, describing VELOCIMOUSE® technology). Human variable regions from intact antibodies generated by such animals may be further modified, e.g., by combining with a different human constant region.
[0155] Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al., Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006). Additional methods include those described, for example, in U.S. Patent No. 7,189,826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27(3): 185-91 (2005).
[0156] Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.
[0157] In some embodiments, the anti-TGF[33 antibody is a full-length antibody.
[0158] In some embodiments, the anti-TGF|33 antibody is an antibody fragment. In some embodiments, the anti-TGF|33 antibody fragment is selected from the group consisting of an Fv, single-chain Fv (scFv), Fab, Fab', or (Fab')2 and other fragments described below. For a review of certain antibody fragments, see Hudson et al. Nat. Med. 9: 129-134 (2003). For a review of scFv fragments, see, e.g., Pluckthiin, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Patent Nos. 5,571,894 and 5,587,458. For discussion of Fab and F(ab’)2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Patent No. 5,869,046.
[0159] Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 404,097; WO 1993 / 01161; Hudson et al., Nat. Med. 9: 129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9: 129-134 (2003).
[0160] Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516 Bl).
[0161] Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g., E. coli or phage), as described herein.
[0162] In some embodiments, the anti-TGF[33 antibody is an IgGl or IgG4 isotype. In some embodiments, the anti-TGFp3 antibody is an IgGl isotype. In some embodiments, the anti-TGFp3 antibody is an IgG4 isotype. In some embodiments, the anti-TGFp3 antibody is an IgGl or IgG4 isotype. In some embodiments, the anti-TGFp3 antibody is an IgGl isotype. In some embodiments, the anti-TGFp3 antibody is an IgG4 isotype.
[0163] In some embodiments, the anti-TGFp3 antibody comprises an Fc region. In some embodiments, the anti-TGFp3 antibody comprises a substitution mutation in the Fc region at amino acid residue N297, L234, L235, and / or D265 (EU numbering). In some embodiments, the anti-TGFp3 antibody comprises a substitution mutation selected from the group consisting of N297G, N297A, L234A, L235A, and D265A. In some embodiments, the anti- TGFP3 antibody comprises a substitution mutation in the Fc region at amino acid residue N297 (EU numbering). In some embodiments, the anti-TGFp3 antibody comprises a substitution mutation in the Fc region at amino acid residue L234 (EU numbering). In someembodiments, the anti-TGFp3 antibody comprises a substitution mutation in the Fc region at amino acid residue L235 (EU numbering). In some embodiments, the anti-TGFp3 antibody comprises a substitution mutation in the Fc region at amino acid residue D265 (EU numbering). In some embodiments, the substitution mutation in the Fc region of the anti- TGFP3 antibody is at amino acid residue N297 (EU numbering). In some embodiments, the substitution mutation in the Fc region of the anti-TGFp3 antibody is at amino acid residue L234 (EU numbering). In some embodiments, the substitution mutation in the Fc region of the anti-TGFp3 antibody is at amino acid residue L235 (EU numbering). In some embodiments, the substitution mutation in the Fc region of the anti-TGFp3 antibody is at amino acid residue D265 (EU numbering). In some embodiments, the substitution mutation in the Fc region of the anti-TGFp3 antibody is N297G.
[0164] It is known in the art that, during the expression and processing of antibodies in a cell culture, C-terminal clipping by carboxypeptidases in the culture medium occurs. In some instances, only the C-terminal lysine residue of the heavy chain is clipped. In other instances, additional residues may be clipped. The sequences provided herein are also intended to encompass variants that occur, e.g., by C-terminal clipping, as a result of the production process.
[0165] It is also known in the art that the C-terminal cleavage process is imprecise and that additional C-terminal residues are cleaved. Accordingly, for each sequence disclosed herein that contains a C-terminal lysine, the corresponding sequence without the two C-terminal residues is also contemplated. In some embodiments, for each sequence disclosed herein that contains a C-terminal lysine, the corresponding sequence without the three C-terminal residues is also contemplated. In some embodiments, for each sequence disclosed herein that contains a C-terminal lysine, the corresponding sequence without the four C-terminal residues is also contemplated. In some embodiments, for each sequence disclosed herein that contains a C-terminal lysine, the corresponding sequence without the five C-terminal residues is also contemplated. In some embodiments, for each sequence disclosed herein that contains a C-terminal lysine, the corresponding sequence without the six C-terminal residues is also contemplated. In some embodiments, for each sequence disclosed herein that contains a C-terminal lysine, the corresponding sequence without the seven C-terminal residues is also contemplated. In some embodiments, for each sequence disclosed herein that contains a C-terminal lysine, the corresponding sequence without the eight C-terminal residues is also contemplated. In some embodiments, for each sequence disclosed herein that contains a C-terminal lysine, the corresponding sequence without the nine C-terminal residues is alsocontemplated. In some embodiments, for each sequence disclosed herein that contains a C -terminal lysine, the corresponding sequence without the ten C-terminal residues is also contemplated. In some embodiments, for each sequence disclosed herein that contains a C-terminal lysine, the corresponding sequence without the eleven C-terminal residues is also contemplated. In some embodiments, for each sequence disclosed herein that contains a C-terminal lysine, the corresponding sequence without the twelve C-terminal residues is also contemplated. In some embodiments, for each sequence disclosed herein that contains a C-terminal lysine, the corresponding sequence without the thirteen C-terminal residues is also contemplated. In some embodiments, for each sequence disclosed herein that contains a C-terminal lysine, the corresponding sequence without the fourteen C-terminal residues is also contemplated. In some embodiments, for each sequence disclosed herein that contains a C-terminal lysine, the corresponding sequence without the fifteen C-terminal residues is also contemplated.Therapeutic Methods And Uses
[0166] One aspect of the disclosure provides a method of treating a TGFP-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGF|33) antibody of the disclosure. In some embodiments, the disclosure provides a method of treating a TGFP-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides a method of treating a TGFP-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In someembodiments, the disclosure provides a method of treating a TGFP-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides a method of treating a TGFP-related disorder in a subject in need thereof, the method comprising administering to the subject h2A10.v4.
[0167] In some embodiments, the TGFP-related disorder is fibrosis. In some embodiments, the fibrosis is a fibrotic condition of the lung, liver, heart, kidney, pancreas, eye, and / or skin.
[0168] In some embodiments, the fibrosis is a fibrotic condition of the lung. In some embodiments, the fibrosis is a lung fibrosis selected from the group consisting of idiopathic pulmonary fibrosis (IPF), idiopathic pulmonary upper lobe fibrosis (Amitani disease), familial pulmonary fibrosis, pulmonary fibrosis (e.g., pulmonary fibrosis secondary to systemic inflammatory diseases such as, rheumatoid arthritis, scleroderma, lupus, cryptogenic fibrosing alveolitis, chronic obstructive pulmonary disease (COPD) or chronic asthma), cystic fibrosis, non-specific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP), progressive massive fibrosis, scleroderma / systemic sclerosis (SSc, including limited cutaneous (IcSSc) and diffuse cutaneous (dcSSc) forms and S Sc-associated interstitial lung disease (SSc-ILD)), bronchiolitis obliterans-organizing pneumonia, connective tissue disease- associated ILD (CT-ILD), hypersensitivity pneumonitis, pulmonary hypertension, pulmonary tuberculosis, silicosis, asbestosis, acute lung injury, and acute respiratory distress (ARD, including bacterial pneumonia induced, trauma-induced, progressive fibrotic interstitial lung disease (PF-ILD), and viral pneumonia-induced, ventilator-induced, non-pulmonary sepsis induced). In some embodiments, the lung fibrosis is idiopathic pulmonary fibrosis (IPF). In some embodiments, the lung fibrosis is idiopathic pulmonary upper lobe fibrosis (Amitani disease). In some embodiments, the lung fibrosis is familial pulmonary fibrosis. In some embodiments, the lung fibrosis is pulmonary fibrosis (e.g., pulmonary fibrosis secondary to systemic inflammatory diseases such as. In some embodiments, the lung fibrosis is rheumatoid arthritis. In some embodiments, the lung fibrosis is scleroderma. In some embodiments, the lung fibrosis is lupus. In some embodiments, the lung fibrosis is cryptogenic fibrosing alveolitis. In some embodiments, the lung fibrosis is chronic obstructive pulmonary disease (COPD) or chronic asthma). In some embodiments, the lung fibrosis is cystic fibrosis. In some embodiments, the lung fibrosis is non-specific interstitial pneumonia (NSIP). In some embodiments, the lung fibrosis is cryptogenic organizingpneumonia (COP). In some embodiments, the lung fibrosis is progressive massive fibrosis. In some embodiments, the lung fibrosis is scleroderma / systemic sclerosis (SSc, including limited cutaneous (IcSSc) and diffuse cutaneous (dcSSc) forms and S Sc-associated interstitial lung disease (SSc-ILD)). In some embodiments, the lung fibrosis is bronchiolitis obliterans- organizing pneumonia. In some embodiments, the lung fibrosis is connective tissue disease- associated ILD (CT-ILD). In some embodiments, the lung fibrosis is hypersensitivity pneumonitis. In some embodiments, the lung fibrosis is pulmonary hypertension. In some embodiments, the lung fibrosis is pulmonary tuberculosis. In some embodiments, the lung fibrosis is silicosis. In some embodiments, the lung fibrosis is asbestosis. In some embodiments, the lung fibrosis is acute lung injury. In some embodiments, the lung fibrosis is progressive fibrotic interstitial lung disease (PF-ILD). In some embodiments, the lung fibrosis is acute respiratory distress (ARD, including bacterial pneumonia induced, trauma- induced, and viral pneumonia-induced, ventilator-induced, non-pulmonary sepsis induced).
[0169] In some embodiments, the fibrosis is a fibrotic condition of the liver. In some embodiments, the fibrosis is a fibrotic condition of the liver selected from the group consisting of liver cirrhosis, congenital hepatic fibrosis, obesity, fatty liver, alcohol induced liver fibrosis, non-alcoholic steatohepatitis (NASH), biliary duct injury, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), infection- or viral-induced liver fibrosis (e.g., chronic hepatitis B and C virus infections), cystic fibrosis, autoimmune hepatitis, necrotizing hepatitis, primary sclerosing cholangitis, hemochromatosis, disorders of the biliary tree, and hepatic dysfunction attributable to infections. In some embodiments, the fibrotic condition of the liver is liver cirrhosis. In some embodiments, the fibrotic condition of the liver is congenital hepatic fibrosis. In some embodiments, the fibrotic condition of the liver is obesity. In some embodiments, the fibrotic condition of the liver is fatty liver. In some embodiments, the fibrotic condition of the liver is alcohol induced liver fibrosis. In some embodiments, the fibrotic condition of the liver is non-alcoholic steatohepatitis (NASH). In some embodiments, the fibrotic condition of the liver is biliary duct injury. In some embodiments, the fibrotic condition of the liver is primary biliary cirrhosis (PBC). In some embodiments, the fibrotic condition of the liver is primary sclerosing cholangitis (PSC). In some embodiments, the fibrotic condition of the liver is infection- or viral-induced liver fibrosis (e.g., chronic hepatitis B and C virus infections). In some embodiments, the fibrotic condition of the liver is cystic fibrosis. In some embodiments, the fibrotic condition of the liver is autoimmune hepatitis. In some embodiments, the fibrotic condition of the liver is necrotizing hepatitis. In some embodiments, the fibrotic condition of the liver is primarysclerosing cholangitis. In some embodiments, the fibrotic condition of the liver is hemochromatosis. In some embodiments, the fibrotic condition of the liver is disorders of the biliary tree. In some embodiments, the fibrotic condition of the liver is hepatic dysfunction attributable to infections.
[0170] In some embodiments, the fibrosis is a fibrotic condition of the heart. In some embodiments, the fibrosis is a fibrotic condition of the heart and / or pericardium selected from the group consisting of endomyocardial fibrosis, cardiac allograft vasculopathy (CAV), myocardial infarction, atrial fibrosis, congestive heart failure, arteriosclerosis, atherosclerosis, vascular stenosis, myocarditis, congestive cardiomyopathy, coronary infarcts, varicose veins, coronary artery stenosis and other post- ischemic conditions, and idiopathic retroperitoneal fibrosis. In some embodiments, the fibrotic condition of the heart and / or pericardium is endomyocardial fibrosis. In some embodiments, the fibrotic condition of the heart and / or pericardium is cardiac allograft vasculopathy (CAV). In some embodiments, the fibrotic condition of the heart and / or pericardium is myocardial infarction. In some embodiments, the fibrotic condition of the heart and / or pericardium is atrial fibrosis. In some embodiments, the fibrotic condition of the heart and / or pericardium is congestive heart failure. In some embodiments, the fibrotic condition of the heart and / or pericardium is arteriosclerosis. In some embodiments, the fibrotic condition of the heart and / or pericardium is atherosclerosis. In some embodiments, the fibrotic condition of the heart and / or pericardium is vascular stenosis. In some embodiments, the fibrotic condition of the heart and / or pericardium is myocarditis. In some embodiments, the fibrotic condition of the heart and / or pericardium is congestive cardiomyopathy. In some embodiments, the fibrotic condition of the heart and / or pericardium is coronary infarcts. In some embodiments, the fibrotic condition of the heart and / or pericardium is varicose veins. In some embodiments, the fibrotic condition of the heart and / or pericardium is coronary artery stenosis and other post- ischemic conditions. In some embodiments, the fibrotic condition of the heart and / or pericardium is idiopathic retroperitoneal fibrosis.
[0171] In some embodiments, the fibrosis is a fibrotic condition of the kidney. In some embodiments, the fibrosis is a fibrotic condition of the kidney selected from the group consisting of glomerulonephritis (including membranoproliferative, diffuse proliferative, rapidly progressive or sclerosing, post- infectious and chronic forms), diabetic glomerulosclerosis, focal segmental glomerulosclerosis, IgA nephropathy, diabetic nephropathy, ischemic nephropathy, tubulointerstitial kidney fibrosis, HIV-associated nephropathy, membrane nephropathy, glomerulonephritis secondary to systemicinflammatory diseases such as lupus, scleroderma and diabetes glomerulonephritis, idiopathic membranoproliferative glomerular nephritis, mesangial proliferative glomerulonephritis, crescentic glomerulonephritis, amyloidosis (which affects the kidney among other tissues), autoimmune nephritis, renal tubuloinsterstitial fibrosis, renal arteriosclerosis, Alport’s syndrome, nephrotic syndrome, chronic renal failure, chronic kidney disease, peri glomerular fibrosis / atubular glomeruli, combined apical emphysema and basal fibrosis syndrome (emphysema / fibrosis syndrome), glomerular hypertension, nephrogenic fibrosing dermatopathy, polycystic kidney disease, Fabry’s disease, and renal hypertension. In some embodiments, the fibrotic condition of the kidney is glomerulonephritis. In some embodiments, the fibrotic condition of the kidney is glomerulonephritis (including membranoproliferative, diffuse proliferative, rapidly progressive or sclerosing, post- infectious and chronic forms). In some embodiments, the fibrotic condition of the kidney is diabetic glomerulosclerosis. In some embodiments, the fibrotic condition of the kidney is focal segmental glomerulosclerosis. In some embodiments, the fibrotic condition of the kidney is IgA nephropathy. In some embodiments, the fibrotic condition of the kidney is diabetic nephropathy. In some embodiments, the fibrotic condition of the kidney is ischemic nephropathy. In some embodiments, the fibrotic condition of the kidney is tubulointerstitial kidney fibrosis. In some embodiments, the fibrotic condition of the kidney is HIV-associated nephropathy. In some embodiments, the fibrotic condition of the kidney is membrane nephropathy. In some embodiments, the fibrotic condition of the kidney is glomerulonephritis secondary to systemic inflammatory diseases such as lupus. In some embodiments, the fibrotic condition of the kidney is scleroderma and diabetes glomerulonephritis. In some embodiments, the fibrotic condition of the kidney is idiopathic membranoproliferative glomerular nephritis. In some embodiments, the fibrotic condition of the kidney is mesangial proliferative glomerulonephritis. In some embodiments, the fibrotic condition of the kidney is crescentic glomerulonephritis. In some embodiments, the fibrotic condition of the kidney is amyloidosis (which affects the kidney among other tissues). In some embodiments, the fibrotic condition of the kidney is autoimmune nephritis. In some embodiments, the fibrotic condition of the kidney is renal tubuloinsterstitial fibrosis. In some embodiments, the fibrotic condition of the kidney is renal arteriosclerosis. In some embodiments, the fibrotic condition of the kidney is Alport’s syndrome. In some embodiments, the fibrotic condition of the kidney is nephrotic syndrome. In some embodiments, the fibrotic condition of the kidney is chronic renal failure. In some embodiments, the fibrotic condition of the kidney is chronic kidney disease. In someembodiments, the fibrotic condition of the kidney is peri glomerular fibrosis / atubular glomeruli. In some embodiments, the fibrotic condition of the kidney is combined apical emphysema and basal fibrosis syndrome (emphysema / fibrosis syndrome). In some embodiments, the fibrotic condition of the kidney is glomerular hypertension. In some embodiments, the fibrotic condition of the kidney is nephrogenic fibrosing dermatopathy. In some embodiments, the fibrotic condition of the kidney is polycystic kidney disease. In some embodiments, the fibrotic condition of the kidney is Fabry’s disease. In some embodiments, the fibrotic condition of the kidney is renal hypertension.
[0172] In some embodiments, the fibrosis is a fibrotic condition of the pancreas. In some embodiments, the fibrosis is a fibrotic condition of the pancreas selected from the group consisting of stromal remodeling pancreatitis and stromal fibrosis. In some embodiments, the fibrotic condition of the pancreas is stromal remodeling pancreatitis. In some embodiments, the fibrotic condition of the pancreas is stromal fibrosis.
[0173] In some embodiments, the fibrosis is a fibrotic condition of the gastrointestinal tract. In some embodiments, the fibrosis is a fibrotic condition of the gastrointestinal tract selected from the group consisting of Crohn’s disease, ulcerative colitis, collagenous colitis, colorectal fibrosis, villous atrophy, crypt hyperplasia, polyp formation, healing gastric ulcer, and microscopic colitis. In some embodiments, the fibrotic condition of the gastrointestinal tract is Crohn’s disease. In some embodiments, the fibrotic condition of the gastrointestinal tract is ulcerative colitis. In some embodiments, the fibrotic condition of the gastrointestinal tract is collagenous colitis. In some embodiments, the fibrotic condition of the gastrointestinal tract is colorectal fibrosis. In some embodiments, the fibrotic condition of the gastrointestinal tract is villous atrophy. In some embodiments, the fibrotic condition of the gastrointestinal tract is crypt hyperplasia. In some embodiments, the fibrotic condition of the gastrointestinal tract is polyp formation. In some embodiments, the fibrotic condition of the gastrointestinal tract is healing gastric ulcer. In some embodiments, the fibrotic condition of the gastrointestinal tract is microscopic colitis.
[0174] In some embodiments, the fibrosis is a fibrotic condition of the eye. In some embodiments, the fibrosis is a fibrotic condition of the eye selected from the group consisting of ocular fibrosis, ophthalmic fibrosis, proliferative vitreoretinopathy, vitreoretinopathy of any etiology, fibrosis associated with retinal dysfunction, fibrosis associated with wet or dry macular degeneration, scarring in the cornea and conjunctiva, fibrosis in the corneal endothelium, anterior subcapsular cataract and posterior capsule opacification, anterior segment fibrotic diseases of the eye, fibrosis of the corneal stroma (e.g., associated withcomeal opacification), fibrosis of the trabecular network (e.g., associated with glaucoma), posterior segment fibrotic diseases of the eye, fibrovascular scarring (e.g., in retinal or choroidal vasculature of the eye), retinal fibrosis, epiretinal fibrosis, retinal gliosis, subretinal fibrosis (e.g., associated with age related macular degeneration), tractional retinal detachment in association with contraction of the tissue in diabetic retinopathy, congenital orbital fibrosis, lacrimal gland fibrosis, corneal subepithelial fibrosis, and Grave’s ophthalmopathy. In some embodiments, the fibrotic condition of the eye is ocular fibrosis. In some embodiments, the fibrotic condition of the eye is ophthalmic fibrosis. In some embodiments, the fibrotic condition of the eye is proliferative vitreoretinopathy. In some embodiments, the fibrotic condition of the eye is vitreoretinopathy of any etiology. In some embodiments, the fibrotic condition of the eye is fibrosis associated with retinal dysfunction. In some embodiments, the fibrotic condition of the eye is fibrosis associated with wet or dry macular degeneration. In some embodiments, the fibrotic condition of the eye is scarring in the cornea and conjunctiva. In some embodiments, the fibrotic condition of the eye is fibrosis in the corneal endothelium. In some embodiments, the fibrotic condition of the eye is anterior subcapsular cataract and posterior capsule opacification. In some embodiments, the fibrotic condition of the eye is anterior segment fibrotic diseases of the eye. In some embodiments, the fibrotic condition of the eye is fibrosis of the corneal stroma (e.g., associated with corneal opacification). In some embodiments, the fibrotic condition of the eye is fibrosis of the trabecular network (e.g., associated with glaucoma). In some embodiments, the fibrotic condition of the eye is posterior segment fibrotic diseases of the eye. In some embodiments, the fibrotic condition of the eye is fibrovascular scarring (e.g., in retinal or choroidal vasculature of the eye). In some embodiments, the fibrotic condition of the eye is retinal fibrosis. In some embodiments, the fibrotic condition of the eye is epiretinal fibrosis. In some embodiments, the fibrotic condition of the eye is retinal gliosis. In some embodiments, the fibrotic condition of the eye is subretinal fibrosis (e.g., associated with age related macular degeneration). In some embodiments, the fibrotic condition of the eye is tractional retinal detachment in association with contraction of the tissue in diabetic retinopathy. In some embodiments, the fibrotic condition of the eye is congenital orbital fibrosis. In some embodiments, the fibrotic condition of the eye is lacrimal gland fibrosis. In some embodiments, the fibrotic condition of the eye is corneal subepithelial fibrosis. In some embodiments, the fibrotic condition of the eye is Grave’s ophthalmopathy.
[0175] In some embodiments, the fibrosis is selected from fibrosis resulting from spinal cord injury / fibrosis or central nervous system fibrosis such as fibrosis after a stroke,Duchenne muscular dystrophy, fibrosis associated with neurodegenerative disorder such as Alzheimer’s disease or multiple sclerosis, vascular restenosis, uterine fibrosis, endometriosis, ovarian fibroids, Peyronie’s disease, polycystic ovarian syndrome, disease related pulmonary apical fibrosis in ankylosing spondylitis, scarring, and fibrosis incident to microbial infections (e.g., bacterial, viral, parasitic, fungal). In some embodiments, the fibrosis is fibrosis resulting from spinal cord injury / fibrosis or central nervous system fibrosis such as fibrosis after a stroke. In some embodiments, the fibrosis is Duchenne muscular dystrophy. In some embodiments, the fibrosis is fibrosis associated with a neurodegenerative disorder such as Alzheimer’s disease or multiple sclerosis. In some embodiments, the fibrosis is vascular restenosis. In some embodiments, the fibrosis is uterine fibrosis. In some embodiments, the fibrosis is endometriosis. In some embodiments, the fibrosis is ovarian fibroids. In some embodiments, the fibrosis is Peyronie’s disease. In some embodiments, the fibrosis is polycystic ovarian syndrome. In some embodiments, the fibrosis is disease related pulmonary apical fibrosis in ankylosing spondylitis. In some embodiments, the fibrosis is scarring. In some embodiments, the fibrosis is a fibrosis incident due to microbial infections (e.g., bacterial, viral, parasitic, fungal).
[0176] In some embodiments, the fibrosis is a fibrotic condition of the skin. In some embodiments, the fibrosis of the skin is scleroderma. In some embodiments, the fibrosis of the skin is keloids. In some embodiments, the fibrosis of the skin is morphea.
[0177] In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGF[33 antibody at a dose of about 50 mg to about 1200 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of about 400 mg to about 800 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of about 70 mg to about 80 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of about 215 mg to about 235 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of about 350 mg to about 370 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of about 590 mg to about 610 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of about 1100 mg to about 1200 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of about 75 mg. In some embodiments, themethod of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of about 225 mg. In some embodiments, the method of treating the TGFP- related disorder comprises administering the anti-TGFp3 antibody at a dose of about 360 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of about 600 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of about 1200 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of 50 mg to 1200 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of 400 mg to 800 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of 70 mg to 80 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of 350 mg to 370 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of 590 mg to 610 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of 1100 mg to 1200 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of 75 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of 225 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of 360 mg. In some embodiments, the method of treating the TGFP-related disorder comprises administering the anti-TGFp3 antibody at a dose of 600 mg. In some embodiments, the method of treating the TGFP- related disorder comprises administering the anti-TGFp3 antibody at a dose of 1200 mg.
[0178] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody of the disclosure. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR- H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising theamino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antitransforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject h2A10.v4. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of about 50 mg to about 1200 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of about 400 mg to about 800 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of about 70 mg to about 80 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of about 215 mg to about 235 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of about 350 mg to about 370 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of about 590 mg to about 610 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of about 1100 mg to about 1200 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of about 75 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of about 225 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of about 360 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFP3 antibody at a dose of about 600 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of about 1200 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of 50 mg to 1200 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti- TGFP3 antibody at a dose of 400 mg to 800 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of 70 mg to 80 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of 215 mg to 235 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti- TGFP3 antibody at a dose of 350 mg to 370 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of 590 mg to 610 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of 1100 mg to 1200 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti- TGFP3 antibody at a dose of 75 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of 225 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti- TGFP3 antibody at a dose of 360 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti-TGFp3 antibody at a dose of 600 mg. In some embodiments, the method of treating systemic sclerosis comprises administering the anti- TGFP3 antibody at a dose of 1200 mg.
[0179] In some embodiments, the disclosure provides a method of treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody of the disclosure. In some embodiments, the disclosure provides a method of treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antitransforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprisingthe amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides a method of treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antitransforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the disclosure provides a method of treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides a method of treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, the method comprising administering to the subject h2A10.v4. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of about 50 mg to about 1200 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of about 400 mg to about 800 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of about 70 mg to about 80 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of about 215 mg to about 235 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of about 350 mg to about 370 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of about 590 mg to about 610 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of about 1100 mg to about 1200 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of about 75 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of about 225 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of about 360 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFP3 antibody at a dose of about 600 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of about 1200 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of 50 mg to 1200 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of 400 mg to 800 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of 70 mg to 80 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti- TGFP3 antibody at a dose of 215 mg to 235 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of 350 mg to 370 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of 590 mg to 610 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of 1100 mg to 1200 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of 75 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of 225 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti- TGFP3 antibody at a dose of 360 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of 600 mg. In some embodiments, the method of treating idiopathic pulmonary fibrosis (IPF) comprises administering the anti-TGFp3 antibody at a dose of 1200 mg.
[0180] In some embodiments, the disclosure provides a method of treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody of the disclosure. In some embodiments, the disclosure provides a method of treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ IDNO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides a method of treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the disclosure provides a method of treating progressive fibrotic interstitial lung disease (PF- ILD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides a method of treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, the method comprising administering to the subject h2A10.v4. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti-TGFp3 antibody at a dose of about 50 mg to about 1200 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti-TGFp3 antibody at a dose of about 400 mg to about 800 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti-TGFp3 antibody at a dose of about 70 mg to about 80 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti-TGFp3 antibody at a dose of about 215 mg to about 235 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti-TGFp3 antibody at a dose of about 350 mg to about 370 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti-TGFp3 antibody at a dose of about 590 mg to about 610 mg. In some embodiments, the method of progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti-TGFp3 antibody at a dose of about 1100 mg to about 1200 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti- TGFP3 antibody at a dose of about 75 mg. In some embodiments, the method of treatingprogressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti- TGFP3 antibody at a dose of about 225 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti- TGFP3 antibody at a dose of about 360 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti- TGFP3 antibody at a dose of about 600 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti- TGFP3 antibody at a dose of about 1200 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti- TGFP3 antibody at a dose of 50 mg to 1200 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti-TGFp3 antibody at a dose of 400 mg to 800 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti-TGFp3 antibody at a dose of 70 mg to 80 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti-TGFp3 antibody at a dose of 215 mg to 235 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti-TGFp3 antibody at a dose of 350 mg to 370 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti-TGFp3 antibody at a dose of 590 mg to 610 mg. In some embodiments, the method of progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti- TGFP3 antibody at a dose of 1100 mg to 1200 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti-TGFp3 antibody at a dose of 75 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti- TGFP3 antibody at a dose of 225 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti- TGFP3 antibody at a dose of 360 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti- TGFP3 antibody at a dose of 600 mg. In some embodiments, the method of treating progressive fibrotic interstitial lung disease (PF-ILD) comprises administering the anti- TGFP3 antibody at a dose of 1200 mg.
[0181] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subjectabout 50 mg to about 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0182] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 50 mg to 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0183] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 70 mg to about 80 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 75 mg of an anti-transforming growth factor beta 3 (TGF[33) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence ofSEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0184] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 215 mg to about 235 mg of an anti -transforming growth factor beta 3 (TGF[33) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 225 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0185] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 350 mg to about 370 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 360 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acidsequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0186] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 590 mg to about 610 mg of an anti -transforming growth factor beta 3 (TGF|33) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 600 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0187] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 1100 mg to about 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein theanti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0188] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 70 mg to 80 mg of an anti-transforming growth factor beta 3 (TGF[33) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 75 mg of an antitransforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0189] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 215 mg to 235 mg of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in asubject in need thereof, the method comprising administering to the subject 225 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0190] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 350 mg to 370 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 360 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0191] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 590 mg to 610 mg of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO:5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 600 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0192] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 1100 mg to 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a HCDRVR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
[0193] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0194] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 50 mg to about 1200 mg of an anti-transforming growth factor beta 3 (TGF|33) antibody, wherein the anti-TGF|33 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0195] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 50 mg to 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0196] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 70 mg to about 80 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 75 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0197] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 215 mg to about 235 mg of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 225 mg of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0198] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 350 mg to about 370 mg of an anti-transforming growth factor beta 3 (TGF|33) antibody, wherein the anti-TGF|33 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 360 mg of an anti-transforming growth factor beta 3 (TGF|33) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0199] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 590 mg to about 610 mg of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 600 mg of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0200] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 1100 mg to about 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0201] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 70 mg to 80 mg of an anti-transforming growth factor beta 3 (TGF|33) antibody, wherein the anti-TGF|33 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 75 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0202] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 215 mg to 235 mg of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 225 mg of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0203] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 350 mg to 370 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 360 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0204] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 215 mg to 235 mg of an anti -transforming growth factor beta 3 (TGF|33) antibody, wherein the anti-TGF|33 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 600 mg of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0205] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 1100 mg to 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0206] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0207] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 50 mg to about 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0208] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 50 mg to 1200 mg of an anti-transforming growth factor beta 3 (TGF[33) antibody, wherein the anti-TGF|33 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0209] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 70 mg to about 80 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 75 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0210] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 215 mg to about 235 mg of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 225 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0211] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 350 mg to about 370 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 360 mg of an anti-transforming growth factor beta 3 (TGF[33) antibody,wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0212] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 590 mg to about 610 mg of an anti -transforming growth factor beta 3 (TGF|33) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 600 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0213] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 1100 mg to about 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0214] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 70 mg to 80 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 75 mg of an antitransforming growth factor beta 3 (TGF[33) antibody, wherein the anti-TGFp3 antibodycomprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0215] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 215 mg to 235 mg of an anti -transforming growth factor beta 3 (TGF[33) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 225 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0216] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 350 mg to 370 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 360 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0217] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 590 mg to 610 mg of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 600 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0218] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject1100 mg to 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 1200 mg of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0219] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 50 mg to about 1200 mg of h2A10.v4.
[0220] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 50 mg to 1200 mg of h2A10.v4.
[0221] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 70 mg to about 80 mg of h2A10.v4. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 75 mg of h2A10.v4.
[0222] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 215 mg to about 235 mg of h2A10.v4. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 225 mg of h2A10.v4.
[0223] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 350 mg to about 370 mg of h2A10.v4. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 360 mg of h2A10.v4.
[0224] In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 590 mg to about 610 mg of h2A10.v4. In some embodiments, the disclosure provides a method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 600 mg of h2A10.v4.
[0225] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 1100 mg to about 1200 mg of h2A10.v4. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject about 1200 mg of h2A10.v4.
[0226] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 70 mg to 80 mg of h2A10.v4. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 75 mg of h2A10.v4.
[0227] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 215 mg to 235 mg of h2A10.v4. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 225 mg of h2A10.v4.
[0228] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 350 mg to 370 mg of h2A10.v4. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 360 mg of h2A10.v4.
[0229] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 590 mg to 610 mg of h2A10.v4. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 600 mg of h2A10.v4.
[0230] In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 1100 mg to 1200 mg of h2A10.v4. In some embodiments, the present disclosure provides methods of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject 1200 mg of h2A10.v4.
[0231] One aspect of the disclosure provides an anti -transforming growth factor beta 3 (TGF[33) antibody as disclosed herein for use in treating a TGFP-related disorder in a subject in need thereof. In some embodiments, the disclosure provides an anti-TGF[33 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 50 mg to about 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 400 mg to about 800 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 70 mg to about 80 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 215 mg to about 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP- related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 350 mg to about 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 590 mg to about 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 1100 mg to about 1200 mg. In some embodiments, thedisclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 75 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 225 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 360 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 600 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 50 mg to 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 400 mg to 800 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 70 mg to 80 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 215 mg to 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 350 mg to 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 590 mg to 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 1100 mg to 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 75 mg. In some embodiments, the disclosure providesan anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 225 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP- related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 360 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti- TGFP3 antibody is administered at a dose of 600 mg. In some embodiments the disclosure provides an anti-TGFp3 antibody for use in treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 1200 mg.
[0232] In some embodiments, the disclosure provides an anti-transforming growth factor beta 3 (TGFP3) antibody as disclosed herein for use in treating systemic sclerosis in a subject in need thereof. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti- TGFP3 antibody is administered at a dose of about 50 mg to about 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 400 mg to about 800 mg. In some embodiments, the disclosure provides ananti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 70 mg to about 80 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 215 mg to about 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 350 mg to about 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 590 mg to about 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 1100 mg to about 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti- TGFP3 antibody is administered at a dose of about 75 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 225 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 360 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 600 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 50 mg to 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 400 mg to 800 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 70 mg to 80 mg. In some embodiments, the disclosure provides an anti-TGFp3antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti- TGFP3 antibody is administered at a dose of 215 mg to 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 350 mg to 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 590 mg to 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 1100 mg to 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 75 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 225 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 360 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 600 mg. In some embodiments the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 1200 mg.
[0233] In some embodiments, the disclosure provides an anti-transforming growth factor beta 3 (TGFP3) antibody as disclosed herein for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof. In some embodiments, the disclosure provides an anti- TGFP3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti- TGFP3 antibody comprises a heavy chain variable region (VH) comprising the amino acidsequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti- TGFP3 antibody is h2A10.v4. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 50 mg to about 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 400 mg to about 800 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 70 mg to about 80 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 215 mg to about 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 350 mg to about 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 590 mg to about 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 1100 mg to about 1200 mg. In some embodiments, the disclosure provides an anti- TGFP3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 75 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 225 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 360 mg. Insome embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 600 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti- TGFP3 antibody is administered at a dose of 50 mg to 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 400 mg to 800 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 70 mg to 80 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 215 mg to 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 350 mg to 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 590 mg to 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 1100 mg to 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 75 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 225 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 360 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis(IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 600 mg. In some embodiments the disclosure provides an anti-TGFp3 antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti- TGFP3 antibody is administered at a dose of 1200 mg.
[0234] In some embodiments, the disclosure provides an anti-transforming growth factor beta 3 (TGFP3) antibody as disclosed herein for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR- L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti- TGFP3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti- TGFP3 antibody is h2A10.v4. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 50 mg to about 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 400 mg to about 800 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 70 mg to about 80 mg.In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 215 mg to about 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti- TGFP3 antibody is administered at a dose of about 350 mg to about 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti- TGFP3 antibody is administered at a dose of about 590 mg to about 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti- TGFP3 antibody is administered at a dose of about 1100 mg to about 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti- TGFP3 antibody is administered at a dose of about 75 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 225 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 360 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 600 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of about 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 50 mg to 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 215 mg to 235 mg. In some embodiments, thedisclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 70 mg to 80 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 225 mg to 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 350 mg to 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 590 mg to 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 1100 mg to 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 75 mg. In some embodiments, the disclosure provides an anti- TGFP3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 225 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 360 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti- TGFP3 antibody is administered at a dose of 600 mg. In some embodiments the disclosure provides an anti-TGFp3 antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody is administered at a dose of 1200 mg.
[0235] In some embodiments, the disclosure provides an anti-TGF|33 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of about 50 mg to about 1200 mg.
[0236] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of 50 mg to 1200 mg.
[0237] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of about 70 mg to about 80 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of about 75 mg.
[0238] In some embodiments, the disclosure provides an anti-TGF[33 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chainvariable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of about 215 mg to about 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of about 225 mg.
[0239] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of about 350 mg to about 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of about 360 mg.
[0240] In some embodiments, the disclosure provides an anti-TGF[33 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chainvariable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of about 590 mg to about 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of about 600 mg.
[0241] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of about 1100 mg to about 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of about 1200 mg.
[0242] In some embodiments, the disclosure provides an anti-TGF[33 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chainvariable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of 70 mg to 80 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of 75 mg.
[0243] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of 215 mg to 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of 225 mg.
[0244] In some embodiments, the disclosure provides an anti-TGF[33 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chainvariable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of 350 mg to 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of 360 mg.
[0245] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of 590 mg to 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of 600 mg.
[0246] In some embodiments, the disclosure provides an anti-TGF[33 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chainvariable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of 1100 mg to 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is administered at a dose of 1200 mg.
[0247] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8.
[0248] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of about 50 mg to about 1200 mg.
[0249] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of 50 mg to 1200 mg.
[0250] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of about 70 mg toabout 80 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of about 75 mg.
[0251] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of about 215 mg to about 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of about 225 mg.
[0252] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of about 350 mg to about 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of about 360 mg.
[0253] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of about 590 mg to about 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequenceof SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of about 600 mg.
[0254] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of about 1100 mg to about 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of about 1200 mg.
[0255] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of 70 mg to 80 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of 75 mg.
[0256] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of 215 mg to 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of 225 mg.
[0257] In some embodiments, the disclosure provides an anti-TGF|33 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGF|33 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of 350 mg to 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of 360 mg.
[0258] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of 590 mg to 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of 600 mg.
[0259] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of 1100 mg to 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8; and wherein the anti-TGFp3 antibody is administered at a dose of 1200 mg.
[0260] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibodycomprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10.
[0261] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of about 50 mg to about 1200 mg.
[0262] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of 50 mg to 1200 mg.
[0263] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of about 70 mg to about 80 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of about 75 mg.
[0264] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of about 215 mg to about 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of about 225 mg.
[0265] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibodycomprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of about 350 mg to about 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of about 360 mg.
[0266] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of about 590 mg to about 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of about 600 mg.
[0267] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of about 1100 mg to about 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of about 1200 mg.
[0268] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of 70 mg to 80 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in needthereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of 75 mg.
[0269] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of 215 mg to 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of 225 mg.
[0270] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of 350 mg to 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of 360 mg.
[0271] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of 590 mg to 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of 600 mg.
[0272] In some embodiments, the disclosure provides an anti-TGF|33 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGF|33 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of 1100 mg to 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; and wherein the anti-TGFp3 antibody is administered at a dose of 1200 mg.
[0273] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of about 50 mg to about 1200 mg.
[0274] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of 50 mg to 1200 mg.
[0275] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of about 70 mg to about 80 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4and wherein the anti-TGFp3 antibody is administered at a dose of about 75 mg.
[0276] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of about 215 mg to about 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4and wherein the anti-TGFp3 antibody is administered at a dose of about 225 mg.
[0277] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of about 350 mg toabout 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of about 360 mg.
[0278] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of about 590 mg to about 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4and wherein the anti-TGFp3 antibody is administered at a dose of about 600 mg.
[0279] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of about 1100 mg to about 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of about 1200 mg.
[0280] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of 70 mg to 80 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of 75 mg.
[0281] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of 215 mg to 235 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of 225 mg.
[0282] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of 350 mg to 370 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use intreating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of 360 mg.
[0283] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of 590 mg to 610 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of 600 mg.
[0284] In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of 1100 mg to 1200 mg. In some embodiments, the disclosure provides an anti-TGFp3 antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4 and wherein the anti-TGFp3 antibody is administered at a dose of 1200 mg.
[0285] One aspect of the disclosure provides the use of an anti-transforming growth factor beta 3 (TGFP3) antibody as disclosed herein for the preparation of a medicament for treating a TGFP-related disorder in a subject in need thereof. In some embodiments, the disclosure provides the use of an anti-transforming growth factor beta 3 (TGFP3) antibody as disclosed herein for the preparation of a medicament for treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides the use of an anti-transforming growth factor beta 3 (TGFP3) antibody as disclosed herein for the preparation of a medicament for treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the disclosure provides the use of an antitransforming growth factor beta 3 (TGFP3) antibody as disclosed herein for the preparation of a medicament for treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides the use of an anti-transforming growth factor beta 3 (TGFP3) antibody as disclosed herein for the preparation of a medicament for treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody is h2A10.v4. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of about 50 mg to about 1200 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of about 400 mg to about 800 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of about 70 mg to about 80 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of about 225 mg to about 235 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of about 350 mg to about 370 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of about 590 mg to about 610 mg. In some embodiments, the medicament is for treating the TGFP- related disorder at a dose of about 1100 mg to about 1200 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of about 75 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of about 225 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of about 360 mg. In some embodiments, the medicament is for treating the TGFP- related disorder at a dose of about 600 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of about 1200 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of 50 mg to 1200 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of 400 mg to 800 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of 70 mg to 80 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of 225 mg to 235 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of 350 mg to 370 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of 590 mg to 610 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of 1100 mg to 1200 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of 75 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of 225 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of 360 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of600 mg. In some embodiments, the medicament is for treating the TGFP-related disorder at a dose of 1200 mg.
[0286] In some embodiments, the disclosure provides the use of an anti-transforming growth factor beta 3 (TGF|33) antibody as disclosed herein for the preparation of a medicament for treating systemic sclerosis in a subject in need thereof. In some embodiments, the disclosure provides the use of an anti-TGFp3 antibody for the preparation of a medicament for treating systemic sclerosis in a subject in need thereof, wherein the anti- TGFP3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides the use of an anti-transforming growth factor beta 3 (TGFP3) antibody as disclosed herein for the preparation of a medicament for treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the disclosure provides the use of an anti-transforming growth factor beta 3 (TGFP3) antibody as disclosed herein for the preparation of a medicament for treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides the use of an anti-transforming growth factor beta 3 (TGFP3) antibody as disclosed herein for the preparation of a medicament for treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject h2A10.v4. In some embodiments, the medicament is for treating systemic sclerosis at a dose of about 50 mg to about 1200 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of about 400 mg to about 800 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of about 70 mg to about 80 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of about 215 mg to about 235 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of about 350 mg to about 370 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of about 590 mg to about 610 mg. In some embodiments, themedicament is for treating systemic sclerosis at a dose of about 1100 mg to about 1200 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of about 75 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of about 225 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of about 360 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of about 600 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of about 1200 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of 50 mg to 1200 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of 400 mg to 800 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of 70 mg to 80 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of 225 mg to 235 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of 350 mg to 370 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of 590 mg to 610 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of 1100 mg to 1200 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of 75 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of 225 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of 360 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of 600 mg. In some embodiments, the medicament is for treating systemic sclerosis at a dose of 1200 mg.
[0287] In some embodiments, the disclosure provides the use of an anti-transforming growth factor beta 3 (TGF|33) antibody as disclosed herein for the preparation of a medicament for treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof. In some embodiments, the disclosure provides the use of an anti-TGF|33 antibody for the preparation of a medicament for treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides the use of an anti-transforming growth factor beta 3 (TGF|33) antibody as disclosed herein for the preparation of a medicament for treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFP3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the disclosure provides the use of an anti-transforming growth factor beta 3 (TGFP3) antibody as disclosed herein for the preparation of a medicament for treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides the use of an antitransforming growth factor beta 3 (TGFP3) antibody as disclosed herein for the preparation of a medicament for treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, the method comprising administering to the subject h2A10.v4. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of about 50 mg to about 1200 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of about 400 mg to about 800 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of about 70 mg to about 80 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of about 215 mg to about 235 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of about 350 mg to about 370 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of about 590 mg to about 610 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of about 1100 mg to about 1200 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of about 75 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of about 225 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of about 360 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of about 600 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of about 1200 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of 50 mg to 1200 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of 400 mg to 800 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of 70 mg to 80 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of 215 mg to 235 mg. In some embodiments, the medicament is for treatingidiopathic pulmonary fibrosis (IPF) at a dose of 350 mg to 370 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of 590 mg to 610 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of 1100 mg to 1200 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of 75 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of 225 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of 360 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of 600 mg. In some embodiments, the medicament is for treating idiopathic pulmonary fibrosis (IPF) at a dose of 1200 mg.
[0288] In some embodiments, the disclosure provides the use of an anti-transforming growth factor beta 3 (TGF|33) antibody as disclosed herein for the preparation of a medicament for treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof. In some embodiments, the disclosure provides the use of an anti-TGF|33 antibody for the preparation of a medicament for treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR- L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the disclosure provides the use of an anti-transforming growth factor beta 3 (TGFP3) antibody as disclosed herein for the preparation of a medicament for treating progressive fibrotic interstitial lung disease (PF- ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 8. In some embodiments, the disclosure provides the use of an anti-transforming growth factor beta 3 (TGFP3) antibody as disclosed herein for the preparation of a medicament for treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the disclosure provides the use of an anti-transforming growth factor beta 3 (TGFP3) antibody as disclosed herein for the preparation of a medicament for treatingprogressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, the method comprising administering to the subject h2A10.v4. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of about 50 mg to about 1200 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of about 400 mg to about 800 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of about 70 mg to about 80 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of about 215 mg to about 235 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of about 350 mg to about 370 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of about 590 mg to about 610 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of about 1100 mg to about 1200 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of about 75 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of about 225 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of about 360 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of about 600 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of about 1200 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of 50 mg to 1200 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of 400 mg to 800 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of 70 mg to 80 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of 225 mg to 235 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of 350 mg to 370 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of 590 mg to 610 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of 1100 mg to 1200 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of 75 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitiallung disease (PF-ILD) at a dose of 225 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of 360 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of 600 mg. In some embodiments, the medicament is for treating progressive fibrotic interstitial lung disease (PF-ILD) at a dose of 1200 mg.
[0289] In some embodiments, the disclosure provides the use of an anti-TGF|33 antibody for the preparation of a medicament for treating systemic sclerosis in a subject in need thereof, wherein the anti-TGF|33 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is formulated for administration at a dose of about 50 mg to about 1200 mg.
[0290] In some embodiments, the disclosure provides the use of an anti-TGFp3 antibody for the preparation of a medicament for treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the anti-TGFp3 antibody is formulated for administration at a dose of 50 mg to 1200 mg.
[0291] In some embodiments, the disclosure provides the use of an anti-TGFp3 antibody for the preparation of a medicament for treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino aci...
Claims
CLAIMSWhat is claimed is:
1. A method of treating a TGFP-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antitransforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
2. A method of treating systemic sclerosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
3. A method of treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an antitransforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
4. A method of treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti-transforming growth factor beta 3 (TGFP3) antibody, wherein the anti- TGFP3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
5. A method of inhibiting binding of TGFP3 to TGFBR2 in a subject comprising administering to the subject a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO:1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
6. The method according to any one of claims 1-5, wherein the anti-TGFp3 antibody is administered at a dose of about 50 mg to about 1200 mg.
7. The method according to any one of claims 1-6, wherein the anti-TGFp3 antibody is administered at a dose of about 400 mg to about 800 mg.
8. The method according to any one of claims 1-6, wherein the anti-TGFp3 antibody is administered at a dose of about 70 mg to about 80 mg.
9. The method according to claims 8, wherein the anti-TGFp3 antibody is administered at a dose of about 75 mg.
10. The method according to any one of claims 1-6, wherein the anti-TGFp3 antibody is administered at a dose of about 215 mg to about 235 mg.
11. The method according to claims 10, wherein the anti-TGFp3 antibody is administered at a dose of about 225 mg.
12. The method according to any one of claims 1-6, wherein the anti-TGFp3 antibody is administered at a dose of about 350 mg to about 370 mg.
13. The method according to claim 12, wherein the anti-TGFp3 antibody is administered at a dose of about 360 mg.
14. The method according to any one of claims 1-7, wherein the anti-TGFp3 antibody is administered at a dose of about 590 mg to about 610 mg.
15. The method according to claims 14, wherein the anti-TGFp3 antibody is administered at a dose of about 600 mg.
16. The method according to any one of claims 1-7, wherein the anti-TGFp3 antibody is administered at a dose of about 1100 mg to about 1200 mg.
17. The method according to claim 16, wherein the anti-TGFp3 antibody is administered at a dose of about 1200 mg.
18. The method according to any one of claims 1-17, wherein the heavy chain variable region (VH) comprises at least 95%, sequence identity to the amino acid sequence of SEQ ID NO: 7.
19. The method according to any one of claims 1-18, wherein the light chain variable region (VL) comprises at least 95%, sequence identity to the amino acid sequence of SEQ ID NO: 8.
20. The method according to any one of claims 1-19, wherein the heavy chain variable region (VH) comprises at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 7 and the light chain variable region (VL) comprises at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8.
21. The method according to any one of claims 1-20, wherein the anti-TGFp3 antibody comprises a heavy (H) chain comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9.
22. The method according to any one of claims 1-21, wherein the anti-TGFp3 antibody comprises a light (L) chain comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10.
23. The method according to any one of claims 1-22, wherein the anti-TGFp3 antibody comprises (a) a heavy (H) chain comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9; and (b) a light (L) chain comprising at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10.
24. The method according to any one of claims 1-23, wherein the anti-TGFp3 antibody comprises (a) a heavy (H) chain comprising the amino acid sequence of SEQ ID NO: 9; and (b) a light (L) chain comprising the amino acid sequence of SEQ ID NO: 10.
25. The method according to any one of claims 1-24, wherein the anti-TGFp3 antibody is administered subcutaneously.
26. The method according to any one of claims 1-25, wherein the anti-TGFp3 antibody is administered at a frequency selected from the group consisting of Q1W, Q2W, Q3W, Q4W, Q5W, and Q6W.
27. The method according to claim 26, wherein the anti-TGFp3 antibody is administered in a dosing regimen comprising more than 1 cycle.
28. The method according to claim 26, wherein the anti-TGFp3 antibody is administered in a dosing regimen comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 cycles.
29. The method according to any one of claims 1-25, wherein the anti-TGFp3 antibody is administered subcutaneously at a frequency of Q4W in a dosing regimen comprising 3 cycles.
30. The method according to any one of claims 2 and 6-29, wherein the systemic sclerosis is limited cutaneous systemic sclerosis or diffuse cutaneous systemic sclerosis.
31. The method according to claim 30, wherein the systemic sclerosis is limited cutaneous systemic sclerosis.
32. The method according to claim 30, wherein the systemic sclerosis is diffuse cutaneous systemic sclerosis.
33. An anti-transforming growth factor beta 3 (TGFP3) antibody for use in treating a TGFP- related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR- L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
34. An anti-transforming growth factor beta 3 (TGFP3) antibody for use in treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
35. An anti -transforming growth factor beta 3 (TGFP3) antibody for use in treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
36. An anti-transforming growth factor beta 3 (TGFP3) antibody for use in treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ IDNO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
37. An anti-transforming growth factor beta 3 (TGFP3) antibody for use in inhibiting binding of TGFP3 to TGFBR2 in a subject, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
38. The anti-TGFp3 antibody for use according to any one of claims 33-37, wherein the anti- TGFP3 antibody is administered at a dose of about 50 mg to about 1200 mg.
39. Use of a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody for the manufacture of a medicament for treating a TGFP-related disorder in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
40. Use of a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody for the manufacture of a medicament for treating systemic sclerosis in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR- H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
41. Use of a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody for the manufacture of a medicament for treating idiopathic pulmonary fibrosis (IPF) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR- L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
42. Use of a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody for the manufacture of a medicament for treating progressive fibrotic interstitial lung disease (PF-ILD) in a subject in need thereof, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
43. Use of a therapeutically effective amount of an anti -transforming growth factor beta 3 (TGFP3) antibody for the manufacture of a medicament for inhibiting binding of TGFP3 to TGFBR2 in a subject, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CORFU comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
44. The use according to any one of claims 39-43, wherein the anti-TGFp3 antibody in the medicament is formulated for administration or is to be administered at a dose of about 50 mg to about 1200 mg.
45. An article of manufacture comprising a subcutaneous administration device, wherein the device comprises about 50 mg to about 1200 mg of an anti-TGFp3 antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
46. A subcutaneous pharmaceutical composition comprising about 50 mg to about 1200 mg of an anti-TGFp3 antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and a pharmaceutically acceptable carrier.
47. An intravenous pharmaceutical composition comprising about 50 mg to about 1200 mg of an anti-TGFp3 antibody, wherein the anti-TGFp3 antibody comprises a) a heavy chain variable region comprising a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1; a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; and b) a light chain variable region comprising a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6; and a pharmaceutically acceptable carrier.
Citation Information
Patent Citations
Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof
EP0404097A2
Method for stabilization of proteins using non-natural amino acids
US20040214988A1
Methods of modifying eukaryotic cells
US20070061900A1
Anti-FGFR2 / 3 antibodies and methods using same
US20160244525A1
Isoform-selective Anti-TGF-beta antibodies and methods of use
US20210301005A1
